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1.1 Parkinson’s disease 
1.1.1 Epidemiology 
Parkinson’s disease (PD) is the most common movement disorder and the second most 
common neurodegenerative disease after Alzheimer’s disease with a prevalence of 
approximately 0.3% of the general population in industrialized countries [165, 238, 247, 260]. 
The mean age of onset is estimated to be in the mid-to-late 60s [130, 162]. Whereas the 
disease is rare in young adults (prevalence ~0.25% in the population under 50), its prevalence 
increases to approximately 4% in people over 85 years clearly indicating that PD is an age-
dependent disease [21]. According to several studies, prevalence rates in men are higher than 
in women [20, 50, 73, 174, 192], however, reports of similar prevalence rates in men and 
women also exist [247, 248, 306]. 
1.1.2 Symptomatology 
Symptoms of PD are traditionally divided into two major categories: (1) motor symptoms, 
and (2) non-motor symptoms. 
1.1.2.1 Motor symptoms 
The major clinical picture of PD is the so called parkinsonism. Parkinsonism is an umbrella 
term for a clinical syndrome featuring Parkinson’s-type motor symptoms: slowness of 
movement (bradykinesia), muscle rigidity (rigor), and rest tremor (4-6 Hz) [231]. The 
German Society of Neurology (Deutsche Gesellschaft für Neurologie, DGN) lists a fourth 
feature of parkinsonism: postural instability, which was omitted from the international 
guidelines due to its late appearance during the disease process [63, 231]. PD accounts for 
approximately 75% of parkinsonism thereby representing the most common cause. 
Motor symptoms usually appear unilaterally, most commonly in one of the upper extremities, 
and slowly progress to the contralateral and lower limbs, but the initial asymmetry of 
symptoms remains over the whole course of the disease [218, 251, 335]. The parkinsonian 
motor deficits are due to the degeneration of the dopaminergic substantia nigra pars 
compacta (SNc) and evolve when approximately 30% of nigral neurons are degenerated and 
50-60% of striatal dopamine is lost [45, 75, 101, 151]. Disease progression is characterized 
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by increasing severity of motor symptoms, evolvement of additional motor deficits such as 
postural instability, or gait problems, and appearance of treatment-related complications, 
such as L-DOPA-induced dyskinesias [136].  
1.1.2.2 Non-motor symptoms 
Although PD is still considered a movement disorder and the diagnosis is based upon the 
appearance of parkinsonian motor deficits (see chapter 1.1.5), PD is accompanied by a broad 
spectrum of non-motor symptoms (NMS) as well. These NMS fall into four major categories: 
(1) autonomic dysfunctions; (2) disorders of the sleep-wake cycle; (3) neuropsychiatric 
dysfunctions; and (4) sensory dysfunctions [43]. A thorough list of the NMS associated with 
PD is found in Figure 1.1.  
NMS diversity and severity correlates with advancing disease stages. Remarkably, some 
NMS, such as constipation, hyposmia, pain, REM sleep behavior disorder (RBD), and mood 
disorders appear early in the disease process antedating the onset of motor symptoms, and 
are presenting complaints in up to 20% of patients [214]. This often leads to delayed 
diagnosis of PD, referrals to specialists other than neurologists, and inappropriate treatments 
[214, 273, 274]. The time-period, in which certain NMS and subtle motor changes not yet 
qualifying as parkinsonism are present, is the so called prodromal phase of the disease. 
 





The major histopathological hallmarks of PD are: (1) progressive accumulation of 
intraneuronal proteinaceous inclusion bodies called Lewy-bodies (LB) and Lewy-neurites 
(LN) in predetermined brain regions; and (2) dopaminergic neuronal cell death in specific 
subregions of the SNc [30, 75].  
Two types of LBs can be distinguished: brainstem (classical) type and cortical type [65, 172]. 
In hematoxylin and eosin-stained sections, brainstem LBs appear as intracytoplasmic, 
eosinophilic, and spherical bodies of 8-30 μm diameter (Fig. 1.2) [325]. They possess a dense, 
protein-packed core which is surrounded by a clearer peripheral halo. In contrast to this, 
cortical type LBs are irregular in shape and lack a peripheral halo [324]. LBs contain a mixture 
of over 90 different proteins, out of which abnormally misfolded α-synuclein (aSYN) is the 
most prevalent [85, 290, 325]. Hence, PD belongs to a subgroup of neurodegenerative 
proteinopathies called α-synucleinopathies. In stark contrast to the previous assumption that 
LBs are mainly composed of proteins, recent research with highly advanced electron 
tomography technique demonstrated that the major components seem to be fragmented 
membraneous structures resembling vesicles and dysmorphic organelles including 
mitochondria, lysosomes, and autophagosomes [281]. Granular forms of proteins were 
observed to be intermingled in the core of lipid bilayers and fragmented organelles. 
Pathological forms of aSYN have been found in different layers of the LBs and LNs: 
truncated aSYN was found in the core of the aggregates, mixed with the lipids, whereas 
phosphorylated aSYN was typically found in the periphery [200]. The pathophysiological 
implications and biological relevance of these novel findings are still unclear. 
 
Figure 1.2 | Human Lewy body in a nigral neuron.  
Lewy bodies are intraneuronal spheroid eosinophilic structures upon 
hematoxylin and eosin staining. Nigral neurons contain 
neuromelanin, an auto-oxidation product of dopamine. Extracted 
from [112] (Andreas Hartmann, licence: CC BY-NC-ND 3.0). 
Based on histopathological examinations of the topographical distribution of Lewy 
pathology in the brains of unrelated individuals who died of various causes at different ages, 
Braak and colleagues have elaborated a staging system to describe the putative spatio-
temporal pattern of the progression of Lewy pathology in PD [30].  
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The Braak staging system distinguishes six consecutive stages (Fig. 1.3) [30, 31]. In stage 1, 
Lewy pathology is evident in the olfactory bulb (OB) and the medullary dorsal motor nucleus 
of the vagal nerve. From here, the pathology progresses to more rostral regions of the 
brainstem, to the locus coeruleus (LC), gigantocellular nucleus (GRN), and the nucleus 
magnus obscurus pallidus (stage 2).  
In stage 3, the SNc displays the first LBs, next to the affection of other midbrain and basal 
forebrain structures, such as the pedunculopontine nucleus (PPN), the magnocellular nuclei 
of the basal forebrain, the central subnucleus of the amygdala, and the histaminergic 
tuberomamillary nucleus. No overt neurodegeneration of the SNc is observed in this stage. 
These three initial stages are considered to correlate with the prodromal phase of PD, and 
the involvement of the above structures are hypothesized to account for the NMS antedating 
the motor symptomatology (see chapter 1.1.2.2).  
In stage 4, the SNc is markedly demelanized. Additionally, limbic structures including the 
basolateral and accessory cortical nuclei of the amygdala, parts of the bed nuclei of the stria 
terminalis, and the first cortical structure (anteromedial temporal mesocortex) display Lewy 
pathology. The transition from prodromal PD (NMS and subtle motor changes not yet 
qualifying as parkinsonism) to manifest PD (clear signs of parkinsonism) is hypothesized to 
occur between stage 3 (LB pathology in SNc, but no overt neurodegeneration) and stage 4 
(overt neurodegeneration of the SNc) of the Braak staging. In stages 5 and 6, cortical 
pathology gradually spreads over the entire neocortex.   
 
Figure 1.3 | Schematic representation of the Braak staging system of Lewy pathology in Parkinson’s 
disease. Figure adapted from [107]. 
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1.1.4 Hypotheses of disease progression 
Currently, two major theories exist which aim to explain the progression pattern of pathology 
and symptomatology in idiopathic PD: (1) the prion hypothesis; and (2) the hypothesis of 
selective vulnerability [34, 71, 296, 297]. 
1.1.4.1 The prion hypothesis of Parkinson’s disease 
The word prion is derived from ‘proteinaceous infectious particle’ and refers to the (to our 
knowledge) smallest infectious particle devoid of any nucleic acid component [234]. Prion 
variants of the cellular prion protein (PrPSc) are hypothesized to cause a group of diseases 
called transmissible spongiform encephalopathies by triggering the misfolding of the 
naturally occurring, native forms of the prion protein (PrPC) in the neuronal tissue of the 
infected host resulting in the accumulation and deposition of misfolded proteinaceous 
aggregates [52]. The putative pathway for disease progression within the neuronal tissue of 
the infected host is the cell-to-cell transmission of the misfolded prion protein [319]. 
A similar deposition of aggregated aSYN due to conversion of natively unfolded protein to 
misfolded protein takes place in PD, thus defining the disease – similarly to other 
neurodegenerative diseases – as ‘neurodegenerative proteinopathy’ or ‘protein misfolding 
disorder’ [270]. The hypothesis that pathological aSYN is transmissible from a diseased 
neuron (‘donor’) to a primarily healthy neuron (‘recipient’) similar to PrPSc stems from two 
major observations [235]: (1) in 2003, Braak and colleagues published their staging system 
based on the neuropathological assessment of postmortem brains from unrelated humans, 
in which they describe a sequential progression of Lewy pathology in a deterministic caudo-
rostral pattern (see chapter 1.1.3) [30, 31]; (2) in 2008, Kordower and colleagues described 
the development of aSYN aggregates reminiscent of LBs in striatal engrafted embryonic 
mesencephalic dopaminergic cells in postmortem brains of PD patients [6, 149].  
Taken together, the so-called prion concept of PD hypothesizes that toxic forms of aSYN 
are formed within a small cell population, are then transported in the retrograde and/or 
anterograde direction to anatomically interconnected brain regions where they act as seeds 
and trigger the formation of insoluble, aggregated aSYN [99]. Thus, the reason for 
progression of the α-synucleinopathy is believed to rely mostly, if not completely on the 
neuronal connectivity of the affected brain regions. This theory is mainly evidenced by animal 
models induced by the injection of aSYN pre-formed fibrils (PFF’s), in which the inoculated 
PFF’s trigger the aggregation of the endogenous, natively unfolded aSYN into LB- and LN-
like aggregates at the inoculation site and interconnected brain regions (see chapter 1.3.3.2). 
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However, there are also important arguments against the prion hypothesis: (1) retrospective 
histopathological studies showed that between 6.3 and 43% of PD cases did not follow the 
ascending progression pattern proposed by Braak and colleagues [9, 15, 30, 106, 134, 219]; 
(2) development of Lewy-like aggregates in transplanted embryonic cells is seen only in up 
to 5-10% of engrafted neurons [1, 6, 149]; (3) hereditary forms of PD may show substantial 
neuropathological heterogeneity, even in siblings carrying the same genetic mutation. 
Moreover, in some genetic forms of PD, LB development is lacking, implicating that LB-
formation is not required for neuronal dysfunction and degeneration [74, 232, 316]. And (4) 
the hypothesis does not provide an explanation of how aSYN aggregation is initiated in a 
certain subset of neurons. 
1.1.4.2 The hypothesis of selective vulnerability 
On the contrary, the hypothesis of selective vulnerability proposes that not neuronal 
interconnectivity, but rather certain cell-autonomous factors rendering neurons particularly 
susceptible to the disease process are the major determinants of pathology progression. This 
hypothesis is based on the following observations: (1) neuropathologically affected brain 
regions in PD have a set of shared traits, which distinguishes them from non-affected 
structures; (2) neurons adjacent to LB-displaying brain structures do not automatically 
develop Lewy pathology during the disease process, e.g. whereas cholinergic neurons of the 
PPN display Lewy pathology, GABAergic and glutamatergic neurons are devoid of 
aggregates [108]; (3) the progression pattern of Lewy pathology in humans does not exactly 
follow the connectomes of the affected structures; (4) in SNCA-multiplication and -point 
mutation-linked PD, although all neurons are exposed to higher levels or mutated aSYN, not 
all develop aSYN aggregates implicating the presence of certain factors that increase the 
susceptibility of distinct neurons to the disease process [297]. 
According to the theory of selective vulnerability, certain neurons are inherently more 
vulnerable to pathophysiological processes underlying disease initiation and progression, 
whereas other neurons possess intrinsic properties which make them resilient to the 
pathogenic process [326]. Common traits hypothesized to account for the selective 
susceptibility of certain neurons (vulnerability profile) are: (1) long and thinly or 
unmyelinated axons; (2) axonal hyperbranching leading to high energetic demand; (3) 
autonomous pacemaking relying on L-type Ca2+-channels; (4) higher basal rate of oxidative 
phosphorylation in combination with a small reserve capacity; and (5) low Ca2+ buffering 




The clinical diagnosis of PD as defined by the International Movement Disorder Society 
(MDS) consists of two major steps: (1) clinical diagnosis of the typical motor parkinsonism; 
and (2) identification of Parkinson’s disease as the cause of clinical parkinsonism (Fig. 1.4) 
[231]. The diagnostic criteria were constructed to allow both a high sensitivity and specificity 
with two levels of diagnostic certainty: 
1. Clinically established PD: maximal specificity with the goal that at least 90% of patients 
receiving a clinical diagnosis of PD truly have PD (specificity: ≥90%); 
2. Clinically probable PD: balancing specificity and sensitivity values with the goal that at 
least 80% of patients receiving a clinical diagnosis of PD truly have PD (specificity 
≥80%), and at least 80% of patients having PD will receive the clinical diagnosis of 
PD (sensitivity ≥80%). 
In the first step, the diagnosis of parkinsonism is made based upon the presence of the 
cardinal motor features: bradykinesia in combination with rest tremor, muscle rigidity (rigor), 
or both. As parkinsonism is not a specific syndrome of PD and may be associated with 
several other diseases, such as atypical Parkinsonian disorders, or secondary Parkinson 
syndromes [63], in the second step, PD has to be identified as the cause of parkinsonism. 
Three criteria systems are included (Fig. 1.4). 
1. Absolute exclusion criteria must be absent. These refer to clinical features and imaging results 
which suggest an alternate cause of the parkinsonism. For example, the presence of clear 
cerebellar abnormalities suggests the diagnosis of multiple system atrophy; the presence 
of vertical supranuclear gaze palsy is indicative of progressive supranuclear palsy; or 
treatment with a dopamine antagonist, dopamine-depleting agent, or exposure to 
neurotoxins known to induce parkinsonism suggest the diagnosis of drug- or toxin-
induced parkinsonism instead of idiopathic PD. 
2. Red flags should be absent. These refer to clinical symptoms which are rarely associated with 
PD, but do not exclude the possibility of PD being present in the patient. For example, 
severe autonomic failure in the first five years of the disease is suggestive of multiple 
system atrophy, however, does not exclude the possibility of idiopathic PD. 
3. At least two out of four supportive criteria should be present. These include: a clear and dramatic 
response to dopaminergic treatment; classic rest tremor (4-6 Hz); presence of L-DOPA-
induced dyskinesia; and hyposmia and/or cardiac denervation evidenced by 




Figure 1.4 | MDS clinical diagnostic criteria of 





PD is a slowly progressive, highly debilitating disease. Until today, no effective disease-
modifying (neuroprotective) therapy has been developed to slow or even halt disease 
progression [208]. However, pharmacological and non-pharmacological therapies are 
available which can alleviate (mainly) motor symptomatology and thus significantly increase 
the quality of life of patients for many years [207, 341].  
1.1.6.1 Alleviation of motor symptoms 
Since the discovery that dopamine depletion in the striatum of patients is the underlying 
cause of parkinsonism in PD [36, 37], several pharmacological treatments have been 
developed which target nigrostriatal dopaminergic neurotransmission at the presynaptic or 
postsynaptic level.  
L-DOPA or levodopa is a blood-brain barrier crossing precursor of dopamine, which is taken 
up by dopaminergic neurons and subsequently converted into dopamine thereby restoring 
presynaptic dopamine levels in the nigrostriatal system [208]. Still today, L-DOPA is the most 
effective drug to alleviate motor symptoms and therefore represents the gold standard for 
PD therapy [198, 286, 341]. Due to the short plasma half-life of L-DOPA, repeated intake is 
necessary resulting in a pulsatile plasma profile of the drug [292]. In early disease stages, when 
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the L-DOPA and dopamine storage capacity of nigrostriatal nerve terminals is only partially 
decreased, the CNS is hypothesized to effectively buffer the fluctuations of L-DOPA 
concentration. However, in intermediate and advanced disease stages, with severe 
nigrostriatal damage, the pulsatile plasma levels result in pulsatile stimulation of postsynaptic 
striatal dopaminergic receptors, leading to fluctuations in motor symptoms from muscle 
rigidity and akinesia corresponding to low L-DOPA levels to the emergence of dyskinetic 
movements, so called L-DOPA-induced dyskinesias with high L-DOPA levels [211]. To increase 
bioavailability and ameliorate pharmacokinetics of L-DOPA in the CNS, it can be combined 
with the following drugs: (1) peripheral dopamine decarboxylase inhibitors to decrease its 
peripheral conversion to dopamine (standard combination); (2) catechol-O-
methyltransferase (COMT) inhibitors to block its peripheral degradation; or (3) centrally 
acting monoamine oxidase B (MAO-B) inhibitors to decrease its central degradation [208]. 
Another highly effective approach are dopamine receptor agonists which can be applied as 
a monotherapy or in combination with L-DOPA. They exert their antiparkinsonian effect via 
direct activation of D2-, and in part of the D1 receptors abundantly found in the dorsal 
striatum [104, 334]. Their plasma half-life is longer than that of L-DOPA, thus, their 
postsynaptic dopamine receptor activation is more stable over time limiting their potential 
to induce motor fluctuations [206]. Major limiting factors for their usage in monotherapy 
are: (1) dopamine receptor agonists only exert a moderate effect on the parkinsonian motor 
symptomatology; and (2) they induce impulse control disorders, such as compulsive 
gambling, dopamine dysregulation syndrome, or hypersexuality in up to 17% of patients, 
possibly owing to their action on the D3 receptors mainly found in limbic areas of the brain 
[104, 288, 336, 341]. 
The use of anticholinergic drugs is limited to PD patients whose greatest source of disability 
is tremor (tremor-dominant PD), as it shows beneficial effects to alleviate tremor, however, 
has only minor effect on bradykinesia or rigor [341]. Amantadine, a glutamatergic N-methyl-
D-aspartate (NMDA)-receptor blocker, due to its limited efficacy in alleviating parkinsonism, 
is no longer recommended as first-line therapy [341]. However, it has shown good efficacy 
in reducing motor fluctuations and L-DOPA-induced dyskinesia [208]. 
In advanced PD, when pharmacological treatment fails to facilitate adequate relief of motor 
symptoms, or induces severe motor fluctuations, deep brain stimulation (DBS), most 
commonly of the subthalamic nucleus (STN) or the internal division of the globus pallidus 
(GPi) can be taken into consideration as a non-pharmacological treatment [224]. The exact 
mechanism of action of DBS is still poorly understood, however, it is hypothesized to 
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modulate abnormal neuronal activity in the basal ganglio-thalamo-cortical and brainstem 
motor loops [48, 92, 103]. DBS was repeatedly shown to significantly alleviate motor 
symptoms, enable reduction of pharmacological dopaminergic treatment by up to 62%, and 
thus substantially decrease the occurrence of disabling dyskinesias [143].  
Other non-pharmacological treatment options include physiotherapy, active exercise 
therapy, or speech therapy, which were repeatedly shown to be effective in amelioration of 
motor and certain non-motor symptomatology, such as cognitive impairment [63, 66, 294, 
339]. 
1.1.6.2 Alleviation of non-motor symptomatology 
In stark contrast to motor symptoms, NMS are often under-recognized and under-
diagnosed, although their impact on the quality of life of patients may surpass that of motor 
symptoms [13]. A prospective study conducted in the US showed that depression and anxiety 
diagnoses are missed in around 60%, for fatigue in around 75%, and for sleep disturbance in 
around 40% of consultations by neurologists [284]. Additionally, given the sparse number of 
randomized, double blind, placebo-controlled clinical trials, evidence-based 
recommendations for the treatment of specific NMS are limited. Table 1.1 gives a brief 
















Table 1.1 | Treatment options for specific non-motor symptoms according to [63, 269] 
Non-motor symptom Treatment options 
Depression and other mood 
disorders 
• Sufficient substitution of dopamine 
• Antidepressants 
▪ Tricyclic antidepressants (TCA) 
▪ Selective serotonin reuptake inhibitors (SSRI) 
▪ Serotonin-noradrenaline reuptake inhibitors (SSNRI) 
• Dopaminergic agents, such as pramipexole 
• Psychotherapy, cognitive behavioral therapy 
Mild cognitive impairment • Neuropsychological cognitive training 
Dementia • Cholinesterase inhibitors 
▪ Only: rivastigmine and donepezil 
Psychosis • Treat potential causative factors (e.g. dehydration) 
• Atypical antipsychotics 
▪ Only options: clozapine or quetiapine 
• If psychosis occurs in combination with dementia, cholinesterase inhibitors are 
an alternative 
Insomnia • General sleep hygiene recommendations 
• Reduce night-time motor fluctuations and restless legs syndrome by continuous 
drug delivery or controlled-release formulations 
• Zopiclone 
Orthostatic hypotension • Patient education 
• Non-pharmacological therapies 
▪ Increased salt intake 
▪ Increased water intake 
▪ Compression stockings 
• Pharmacological therapies 
▪ Noradrenaline precursor (droxidopa) 
Urinary dysfunction • Identify and treat other causative factors (e.g. prostate hyperplasia) 
• Sufficient substitution of dopamine 
• Anticholinergics 
Constipation • Non-pharmacological treatment 
▪ Increased fiber- and water intake 
▪ Physical activity 
• Laxative therapy 
▪ Bulk-forming laxatives 




1.3 Animal models of Parkinson’s disease 
Currently, biomedical research relies heavily on animal models to study pathophysiological 
mechanisms, and to develop and test therapeutic strategies for human diseases. An animal 
model was defined by the Institute of Laboratory Animal Resources as [337]: 
“[…] a living organism with an inherited, naturally acquired, or induced pathological 
process that in one or more respects closely resembles the same phenomenon occurring in 
man. Animal models, in this sense, never provide final answers but offer only 
approximations, for no single animal model can ever duplicate a disease in man. Thus, 
animal models should not be expected to be ideal, nor to be universally suited to all 
foreseeable uses. On the other hand, for a model to be a good one, it must provide a new 
insight, have relevance to a particular problem and respond predictably.” 
Animal models, as also stated in the above definition, are not ideal nor universally applicable, 
as no animal model fully recapitulates human disease. However, they provide a crucial 
opportunity to expand our knowledge and understanding of the pathophysiology of certain 
human diseases, and to test therapeutic approaches. To appraise animal models, common 
validation criteria are used: (1) face validity; (2) construct or etiologic validity; (3) predictive 
or pharmacological validity (Fig. 1.5) [338]. 
Face validity indicates whether the animal model recapitulates important symptomatology 
and neuropathology of the disease it models. Animal models of PD with a high face validity 
should therefore mimic the slowly progressive nature of symptomatology, develop 
parkinsonism, and a wide range of non-motor symptoms. Neuropathologically, they should 
display aSYN-aggregates resembling LBs and LNs, nigrostriatal dopaminergic cell loss, and 
degeneration in some non-dopaminergic brain regions. 
Construct or etiologic validity indicates whether the methods used for the construction 
(induction) of the animal model are relevant to the etiology of the human disease, i.e. whether 
the disease in the animal model was triggered by an established cause of the human disease. 
As PD in humans is idiopathic, which means that the underlying etiology of the disease is to 
our current knowledge unknown, no PD animal model has a high level of construct validity. 
However, genetic forms of parkinsonism with mendelian inheritance (e.g. SNCA point 
mutations or duplications/triplication), or toxin-induced parkinsonism can be modelled with 
high construct validity.  
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Predictive or pharmacological validity refers to good response to clinically effective 
pharmacotherapy, which means that a response to treatment in the animal model predicts its 
effectiveness in humans. In PD animal models, high predictive validity indicates good 
responsiveness to symptomatic treatment, and, once available, good responsiveness to 
neuroprotective substances. 
 
Figure 1.5 | Validation criteria of 
animal models of Parkinson’s 
disease. Figure adapted from [46]. 
Currently, PD animal models can be divided into three major groups: (1) traditional, 
neurotoxin-induced models; (2) genetic models; (3) aSYN-based models. 
 
1.3.1 Neurotoxin-induced animal models of Parkinson’s disease 
The first attempts to model PD in animals were based on the systemic or local application 
of distinct neurotoxins inducing nigrostriatal dopaminergic neurodegeneration. These 
models replicate the degeneration of nigrostriatal dopaminergic neurons and as a 
consequence, reproduce the motor symptomatology of PD. However, they lack other 
substantial characteristics: the slowly progressive nature of neuropathology, pathology of 
non-dopaminergic neural networks, extensive non-motor symptomatology, and aSYN 
aggregation. 
6-hydroxydopamine (6-OHDA), a hydroxylated analogue of dopamine, was the firstly 
discovered neurotoxin to selectively damage catecholaminergic neurons [256, 314]. Given its 
hydrophilic nature, systematically administered 6-OHDA cannot cross the blood-brain 
barrier and thus needs to be stereotactically injected into the SNc, the medial forebrain 
bundle (mfb), or the striatum (STR) [118, 135, 225, 268, 291]. It enters the neurons via their 
respective catecholaminergic transporters [dopamine transporter (DAT), noradrenaline 
transporter (NET)] resulting in the relative selectivity of the neurotoxin to catecholaminergic 
neurons. Once inside the cells, three distinct mechanisms are proposed to lead to the 
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observed neurotoxicity: (1) auto-oxidation of 6-OHDA producing highly reactive radicals 
[256]; (2) MAO-catalyzed metabolism resulting in reactive oxygen species (ROS) production; 
(3) inhibition of mitochondrial respiratory chain complexes I (NADH:ubiquinone 
oxidoreductase) and IV (cytochrome x oxidase) resulting in decreased mitochondrial 
membrane potential, diminished ATP production, and generation of ROS [98]. The major 
characteristics of the 6-OHDA model are summarized in Table 1.2.  
In 1983, Langston and colleagues described four cases of severe and permanent chemically 
induced parkinsonism in drug abusers due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), a byproduct in the synthesis of the opioid drug 1-methyl-4-phenyl-4-
propionoxypiperidine (MPPP) [164]. This discovery has prompted the development of new 
experimental animal models of PD based on the application of MPTP. As MPTP is highly 
lipophilic, it readily crosses the blood-brain barrier and thus can be applied systematically 
(usually intraperitoneally or subcutaneously). Once inside the brain, MPTP is converted to 
the intermediate 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) in astroglial cells by 
MAO-B, which then spontaneously oxidizes to the highly neurotoxic 1-methyl-4-
phenylpyridinium (MPP+) [47, 58, 133]. MPP+ is then taken up via catecholaminergic 
transporters (DAT, and NET) into catecholaminergic, among others dopaminergic neurons. 
Once intracellular, it rapidly accumulates in synaptic vesicles and the mitochondrial matrix 
and exerts its neurotoxic effects by the reversible blockade of the mitochondrial respiratory 
transport chain complex I resulting in depolarization of the mitochondrial inner membrane, 
diminished ATP production, and generation of ROS [113, 204, 244]. The major 
characteristics of the MPTP model are summarized in Table 1.2. 
Numerous epidemiological studies have shown that pesticide exposure was associated with 
a significantly elevated risk to develop PD [12, 64, 86, 119, 302]. This discovery has led to 
the development of additional neurotoxin-based animal models of PD, such as the chronic 
rotenone application-model. Rotenone is a naturally occurring compound, which was 
commonly used as an organic broad spectrum insecticide [26]. It is highly lipophilic and thus, 
upon systemic administration, it readily crosses the blood-brain barrier and plasma 
membrane. Once intracellular, similarly to MPP+, rotenone inhibits the mitochondrial 
respiratory chain complex I thereby decreasing the inner membrane potential, diminishing 
ATP production, and generating ROS [26, 283]. Major characteristics of the rotenone-model 




Table 1.2 | Common characteristics of neurotoxin-induced animal models of PD. Table adapted from [27] 
PD 
model Face validity 
Construct 
validity Predictive validity Uses Limitations 
6-OHDA Lesion and temporal 
manner depends on the 
injection site (SNc, 
mfb, STR) 




• Cell loss SNc > VTA 
• Robust asymmetric 
motor deficits 




• no aSYN-aggregates 
Low level • Dopaminergic 
treatment causes 
rotation due to 
hemiparkinsonism 
• Neuroprotection? 














• Cell loss SNc > VTA 
• Strong motor 
symptoms 




• no aSYN-aggregates 
Subacute/chronic dose: 
• Progressive model 
• Moderate to severe 
degeneration of 
dopaminergic cells 
• Cell loss SNc > VTA 
• Degeneration of 
noradrenergic LC 
neurons 
• aSYN aggregates 
High level for 
MPTP-induced 
parkinsonism 
Low level for 
PD 













• Common and 
cheap preclinical 
model 
• Commonly used in 
mice and NHPs 










• Some motor 
symptoms 




leads to tauopathy 
model 





• Good response to 
dopaminergic 
treatment 





• Environmental risk 
modeling 
• Study aSYN 
aggregation and 
propagation 







1.3.2 Genetic models of Parkinson’s disease 
In 1997, Polymeropoulos and colleagues identified the first mutation leading to an autosomal 
dominantly inherited familial form of PD: it was a missense mutation of the gene encoding 
aSYN (SNCA) resulting in a change of the amino acid alanine to threonine at position 53 
(A53T) in the protein [229]. Soon after this, Spillantini and colleagues discovered that the 
major component of Lewy bodies, the key neuropathological hallmarks of PD, is the protein 
aSYN [290]. Furthermore, duplications and triplications of the SNCA gene have been 
identified as an additional cause of early onset hereditary PD. In these cases, a clear 
relationship between the level of aSYN expression (copy number of the gene) and the age of 
onset, distribution of neuropathology, severity of disease, and pace of progression could be 
observed, implicating a dose-dependent effect of aSYN [42, 128]. These major findings have 
underlined the significance of aSYN in the pathogenesis of PD and prompted the 
development of genetic mouse models of PD based on the overexpression of aSYN. 
The major variables, which have to be considered when evaluating transgenic mouse models 
overexpressing aSYN: (1) the transgene – which aSYN form is overexpressed [wild-type 
(WT), mutated, or truncated]; (2) the promotor which drives the transgene expression (pan-
cellular, pan-neuronal, or selective for certain neuronal subtypes); (3) the genetic background 
of the mouse strain, and whether endogenous murine aSYN is expressed; (4) the level of 
aSYN overexpression (usually ranging between 0.5- to 30-fold of the level of the endogenous 
aSYN) [77].  
Although the developed mouse models recapitulate several key features of human PD, such 
as aSYN aggregation, mild to severe motor symptoms, striatal DA loss, most of the models 
fail to exhibit dopaminergic SNc neuronal death despite the fact that they were constructed 
with a causative mutation of human PD (Table 1.3). Reasons for this might be, among others: 
(1) differential vulnerability to triggers of neurodegeneration in humans compared to rodents, 
similar to that observed in toxin-models of PD [236]; (2) for a fully developed disease 
phenotype, the complex interplay of genetics, cellular and environmental factors are needed, 
such as microbiome dysbiosis [261]; (3) the transgene affects embryonal stages of 
development possibly resulting in compensatory mechanisms impacting the expression of 
the phenotype [153]. Nevertheless, transgenic mouse models are valuable tools to study 
aSYN-induced cellular dysfunction, differential cellular susceptibility to dysregulated aSYN 





Table 1.3 | Common characteristics of exemplary aSYN-based genetic models of PD 
PD 
model Face validity 
Construct 







• aSYN aggregation in 
SNc 
• Severe motor 
symptoms 







• No degeneration of 
dopaminergic neurons 









































• aSYN-aggregates in 
dopaminergic neurons 
• Moderate to severe 
motor symptoms 
• Mild cognitive 
dysfunction 
But: 
• No degeneration of 
dopaminergic neurons 





Low level for 
PD 
























• Mild motor symptoms 
But: 
• No aSYN aggregation 
• No dopaminergic 
degeneration 





Low level for 
PD 





























• Progressive aSYN 
aggregation in 
dopaminergic neurons 
• Striatal DA loss 
• Dopaminergic 
degeneration 
• Motor and gait 
impairments 
Low level • Good response 
to dopaminergic 
treatment 

























• aSYN aggregation in 
dopaminergic neurons 
• Striatal DA loss 
• Motor impairment 
• Mild cognitive 
impairment 
But: 
• No degeneration of 
dopaminergic cells 







Low level for 
PD 
• Good response 





























1.3.3 α-synuclein-based models of Parkinson’s disease 
1.3.3.1 Targeted viral vector mediated overexpression of α-synuclein 
Viral vectors can be used to transfer genetic material and thus induce protein expression in 
cells of non-transgenic animals.  Loco-regional aSYN overexpression in the central nervous 
system of model animals with viral vector-mediated approaches represents a valuable 
alternative to transgenic animal models with numerous distinct advantages: (1) spatial control 
of transgene expression achieved by loco-regional injection of the vectors; (2) temporal 
control of the protein expression as the vectors can be injected in adult animals thus limiting 
the possibility of developmental compensatory mechanisms; (3) the expression level of the 
protein can be titrated allowing the study of dose-dependent effects; (4) it allows the usage 
of multiple species ranging from rodents to non-human primates (NHPs) [317]. 
Nevertheless, as all model systems, viral vector-mediated overexpression models also have 
some potential caveats: (1) intracerebral delivery requires stereotactic injections, which might 
disrupt the blood-brain barrier and injure the brain parenchyma resulting in potential 
confounding effects; (2) the genetic material of some vector systems integrate into the host 
genome potentially leading to insertional mutagenesis; (3) potential toxicity of viral vectors; 
(4) lack of absolute specificity to cell types, or –subtypes; (5) due to the overexpression, 
intracellular aSYN levels are several fold higher than in idiopathic or even SNCA 
multiplication-linked PD are achieved, questioning the relevance of the pathophysiological 
mechanisms leading to the disease phenotype in the experimental model [53, 67]. 
Until now, two viral vector systems have been explored to model PD in animals: recombinant 
adeno-associated viral (rAAV) vectors, and lentiviral vectors (LV). The major characteristics 
of the two viral vector systems are summarized in Table 1.4. As the animal model used in 
this dissertation is based on rAAV vector-mediated overexpression of aSYN, and the rAAV 
vectors are far more commonly used than LVs, we will focus on the rAAV vector system. 
Table 1.4 | Major characteristics of the rAAV and LV vector systems 
 rAAV LV 
Genome ssDNA ssRNA 
Packaging capacity 4.5-5 kilobase 7-7.5 kilobase 
Integration into host genome Rarely No 
Long-lasting gene expression Yes Yes 
Pathogenic No Yes 
Transduction of dividing cells Yes Yes 
Transduction of non-dividing cells Yes Yes 
Host immune response Low Low 
Limitations Low packaging capacity Insertional mutagenesis 
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Recombinant AAV vectors are small, single-stranded DNA (ssDNA) viruses, which per se 
are non-pathogenic and non-replicative and are therefore considered to be safe [317]. Once 
injected in vivo, viral particles are taken up by host cells via receptor-mediated internalization, 
and transported to the nucleus where the viral genome (the transgene) is released and the 
second strand of DNA is replicated. Thereafter, the gene of interest is transcribed leading to 
stable and long-lasting expression of the required protein [175].  
Thus far, eleven serotypes of rAAV vectors are known (rAAV1-11), which differ in their 
antigenic profile and their tissue and cell tropism, i.e. in their ability to transduce different 
tissue- and cell types [40, 342]. To optimize transduction efficiency and tropism of the viral 
vectors, rAAVs can be pseudotyped, that is, the genome of a certain serotype (most 
commonly AAV2) is packed into the capsid derived from a different rAAV serotype [35, 
161, 342]. In these cases, rAAV vectors are named as rAAV2/5, rAAV2/6, etc., where the 
first number refers to the genome serotype, whereas the second number implicates the capsid 
serotype [317]. Specificity of the viral vector can additionally be ameliorated with the choice 
of the promotor driving transgene expression. Whereas cytomegalovirus (CMV) or chicken 
β-actin (CBA) promotors allow robust protein expression, but possess no cell type specificity, 
cell type specific promotors, such as Olig1 (for oligodendroglial cells), synapsin-1 (for 
neuronal cells), or tyrosine hydroxylase (TH) promotor (for dopaminergic and noradrenergic 
neurons) allow the highly specific targeting of determined cell types or –subtypes [60, 182].  
A major advantage of viral vector mediated overexpression is the spatial control of 
expression, that is, they allow the transduction of definite brain regions of interest when 
injected stereotactically [53]. In experimental animals modeling PD, the dopaminergic SNc 
is most commonly targeted with rAAV vectors containing the transgene of human WT or 
mutated aSYN. In contrast to transgenic animal models, viral vector mediated 
overexpression of aSYN driven leads to the accumulation of aggregated aSYN reminiscent 
of human LBs and LNs in dopaminergic neurons, progressive dopaminergic deafferentation 
of the STR and nigrostriatal dopaminergic cell death as well as L-DOPA responsive motor 
deficits mimicking parkinsonism (Table 1.5) [60, 72, 131, 142, 147]. Anterograde transport 
of the expressed human aSYN is observed over long distances to known SNc and ventral 
tegmental area1 output regions, such as the STR, olfactory tubercle, nucleus accumbens, 
lateral septum, and the anterior cingulate cortex [142]. Characteristics of common rAAV- 
and LV-models of PD are summarized in Table 1.5. 
                                                 
1 Dopaminergic cell group adjacent to the SNc. Targeted delivery of viral vectors to the SNc transduce VTA 
neurons as well due to the unspecificity of the viral vectors. 
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Table 1.5 | Common characteristics of exemplary viral vector-based animal models 
PD 
model Face validity 
Construct 









• aSYN aggregation in 
SNc 
• Moderate to severe 
dopaminergic 
degeneration 
• Moderate striatal DA 
loss 
• Mild to moderate 
motor symptoms 














• Expensive and 
time-consuming 


















• Moderate striatal DA 
loss 
• Moderate motor 
deficits 












• Expensive and 
time-consuming 
















• Moderate motor 
deficits 








• Expensive and 
time-consuming 












• aSYN aggregation in 
SNc 
• Severe degeneration 
of dopaminergic 
neurons 
• Moderate motor 
deficits 
Low level • Good response 
to dopaminergic 
treatment 








• Expensive and 
time-consuming 












• aSYN aggregation in 
DMV and AMB 
• Neurodegeneration in 
LC, distant from the 
injection site 
But 
• No degeneration of 
DMX (injection site) 
• No degeneration of 
SNc 










• Potential vector 
toxicity 







• aSYN aggregation in 
SNc 
• Mild to moderate 
degeneration of 
dopaminergic neurons 
• Mild motor 
phenotype 
Low level • Good response 
to dopaminergic 
treatment 
• No beneficial 
effect of GDNF 
therapy 
• Neuroprotection? 











• Potential vector 
toxicity 
• Biosafety issues 
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1.3.3.2 α-synuclein pre-formed fibril models 
In vitro, recombinant monomeric aSYN readily self-aggregates and assembles into highly 
ordered amyloid fibrils reminiscent of aSYN fibrils extracted from LBs of postmortem PD 
brains (Fig. 1.6) [54, 56, 95, 280, 315]. This self-aggregative process can be catalyzed by the 
addition of aSYN PFF’s in which scenario the lag phase (nucleation process) is omitted and 
the exogenously added PFF’s serve as templates for the aggregation facilitating the 
polymerization process (Fig. 1.6) [340]. It is proposed that a similar reaction takes place when 
PFF’s are introduced to in vitro cellular models. It was shown that PFF’s, when added to 
primary neuronal cell cultures are readily taken up by neurons into their intracellular space 
where they seed the recruitment of endogenous aSYN thereby leading to neuronal 
dysfunction and cell death [62, 83, 320, 321]. These observations led to the development of 
in vivo PFF animal models, in which aSYN PFF’s are introduced stereotactically into distinct 
brain regions of WT- or transgenic experimental animals. 
 
Figure 1.6 | Schematic representation of the aggregation process of aSYN in vitro. 
The polymerization of aSYN in vitro can be divided into three phases. In the lag phase or nucleation phase, 
native aSYN monomers become misfolded, assemble into oligomers and build prefibrillar forms of aSYN 
(nucleus). This is followed by the elongation phase, in which the previously developed prefibrillar forms of 
aSYN serve as templates for the aggregation of the aSYN in the solution. In the stationary phase, maximum 
fibril growth has occurred. This process can be catalyzed by the addition of exogenous seeds (PFF’s, dark blue 





PFF models possess numerous advantages: (1) they allow the targeted induction of pathology 
via stereotactic injection into predetermined brain regions (spatial control); (2) PFF’s can be 
introduced into elder animals omitting the possibility of developmental compensatory 
mechanisms as seen in transgenic animal models (temporal control); (3) aSYN aggregation is 
triggered in the presence of physiological aSYN concentrations, which likely resembles the 
pathophysiological state of idiopathic PD more, (4) it allows the usage of multiple species 
ranging from rodents to NHPs [67]. Nevertheless, certain caveats also need to be considered: 
(1) administration of PFF’s need intracerebral injections leading to disruption of the blood-
brain barrier and injury of the brain parenchyma potentially resulting in confounding factors; 
(2) the production and sonication parameters of PFF’s likely influence their seeding capacity 
leading to potentially significant inter-laboratory differences. 
Thus far, PFF’s have been injected into various brain regions, gastric and intestinal wall, and 
even muscle of mice, rats, and NHPs [125, 179, 189, 190, 222, 257]. Regardless of the targeted 
region, PFF inoculation led to formation of hyperphosphorylated, p62-, and Ubi-1-positive 
aSYN aggregates highly reminiscent of human LBs and LNs at the inoculation site. 
Moreover, aggregate formation was not restricted to the vicinity of the injection but also 
involved neuronal structures far away from the site of inoculation. Pathology was found in 
axons as well as somata of neurons in distant brain regions. 
The most often targeted regions to model PD are the STR and SNc. Injection of these two 
brain regions led to aSYN aggregate formation in the SNc, reactive microgliosis at the 
injection site, progressive dopaminergic deafferentation of the STR and nigrostriatal 
dopaminergic cell death manifesting as mild to severe motor symptomatology resembling 
human parkinsonism (Table 1.6). Over time, PFF induced pathology progressed in the brain 
in a stereotypical temporo-spatial manner to regions such as the amygdala, septal nucleus, 
entorhinal, motor, and somatosensory cortices [189].  










Table 1.6 | Common characteristics of PFF-induced animal models 
PD model Face validity Construct validity Predictive validity Uses Limitations 
PFF’s or 
LB extracts 






• aSYN aggregates in 
SNc and in brain 
regions distant from the 
injection site 
• Moderate to severe 
degeneration of SNc 
dopaminergic neurons 
• Moderate to severe 
motor deficits 
Low level • Good response 
to passive 
immunotherapy 
















• aSYN aggregates in OB 
and in brain regions 
distant from the 
injection site 
• Progressive olfactory 
deficit 
• Moderate cell loss in 
the AON 



















• aSYN aggregates in the 
gut and the central 
nervous system distant 
from the injection site 
• Moderate degeneration 
of dopaminergic SNc 
neurons 
• Moderate to severe DA 
loss in the STR 
• Significant reduction of 
DAT SPECT signal in 
the STR 

























• aSYN aggregates in the 
spinal cord and central 
nervous system distant 
from the injection site 
• Mild to severe motor 
impairment 
But 
• No data on SNc 
dopaminergic 
degeneration 








• Requires special 
equipment to 
produce PFF’s 






• Extensive aSYN 
aggregation at the 
injection site and STR 
• Moderate to severe 
degeneration of SNc 
dopaminergic neurons 
But 
• No data on motor 
phenotype 






• Requires special 
equipment to 
produce PFF’s 
• Requires two 
intracranial 
injections 




1.4 The pedunculopontine nucleus 
1.4.1 Functional neuroanatomy of the pedunculopontine nucleus 
The pedunculopontine nucleus (PPN) is a small nucleus located in the dorsal tegmentum of 
the mesencephalon and upper pons. The PPN is neurochemically heterogeneous and 
encompasses three distinct neuronal subtypes: (1) large, darkly staining cholinergic neurons; 
(2) small to medium sized γ-aminobutyric acid-synthetizing (GABAergic) neurons; and (3) 
small glutamatergic neurons [327]. A recent stereological study estimating the ratio of the 
three cell types in the rat PPN revealed that cholinergics make up for approximately 25%, 
glutamatergics for 43%, and GABAergics for around 32% of neurons [181], largely 
confirming older studies reporting similar proportions [327]. The distribution of the different 
neuronal subtypes is not homogeneous over the rostro-caudal extent: small to medium sized 
GABAergic neurons are more abundant in the rostral part of the PPN, whereas large 
cholinergic and glutamatergic neurons are rather found in caudal subregions (Fig. 1.7A) [227]. 
Indeed, the uneven caudo-rostral distribution of cholinergic neurons led to the subdivision 
of the PPN into two major parts: (1) pars dissipatus, mainly comprising small GABAergic 
neurons and a few scattered large, cholinergic neurons in the rostral part; and (2) pars 
compacta, comprising densely clustered large cholinergic neurons intermingled with 
glutamatergic neurons located caudally [212]. 
The projection targets of the three neuronal subtypes are largely different. Single-cell tracing 
studies of cholinergic PPN neurons revealed thin, highly arborizing axons innervating large 
areas of the CNS. Two pathways could be distinguished: (1) an ascending pathway 
innervating brain regions rostral from the PPN; and (2) a descending pathway innervating 
caudal regions such as the pontine reticular formation, and the spinal cord [196]. The 
ascending pathway could be further subdivided into a ventral stream innervating midbrain 
dopaminergic cells, hypothalamic structures, amygdala, and the STN; and a dorsal stream 
innervating vast parts of the thalamus, and the inferior and superior colliculi [196]. Viral 
vector mediated cell-type specific anterograde tracing studies have largely confirmed these 
results and identified additional target regions of cholinergic neurons: medial and lateral 
septal nuclei, basal forebrain structures, midbrain periaqueductal gray, and sublaterodorsal 
tegmental nucleus (Fig. 1.7B) [154]. 
The projectomes of glutamatergic and GABAergic PPN neurons are much more sparsely 
investigated. A recent study utilizing cell-type specific anterograde tracing technique 
investigated target regions of the different PPN neuronal subtypes. They revealed that 
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glutamatergic PPN neurons densely innervated the caudal basal forebrain, limbic areas such 
as the bed nuclei of the stria terminalis, STN, ventral tegmental area, and both parts of the 
substantia nigra. Weak innervation was observed of distinct hypothalamic and thalamic 
regions, and caudal portions of the globus pallidus (Fig. 1.7C) [154]. In contrast to previous 
reports, the majority of axons of GABAergic PPN neurons remained within the boundaries 
of the PPN implicating that these neurons are local inhibitory interneurons rather than 
projection neurons (Fig. 1.7D) [154].  
 
Figure 1.7 | The output projectome of the PPN. 
A. Rostro-caudal distribution of the distinct cellular subtypes in the PPN. Cholinergic and glutamatergic 
neurons are abundantly found in the compact subdivision of PPN laying caudally (PPNc), whereas 
GABAergic neurons are mostly found in the rostral portion called pars dissipatus (PPNd). Figure adapted 
from [227] based on [181]. 
B. Output connectome of the cholinergic PPN based on two tracing studies [154, 196]. 
C. Output connectome of the glutamatergic PPN based on [154]. 
D. Output connectome of the GABAergic PPN based on [154]. 
The PPN receives direct projections from sensory areas such as the superior and inferior 
colliculi; motor areas such as the deep cerebellar nuclei, motor cortex, and basal ganglia 
structures; and from brain structures implicated in the regulation of the sleep/wake cycle 
such as the lateral hypothalamus, tuberomamillary nucleus, and laterodorsal tegmental 
nucleus [19, 105]. However, studies on the cell-type specific input connectomes of the PPN 
are sparse. Only recently a study investigated the input connectomes of the glutamatergic 
Introduction 
26 
and GABAergic PPN using a cell-type specific trans-synaptic rabies virus tracing technique 
[254]. According to this study, glutamatergic PPN neurons receive dense innervation from 
several basal ganglia structures such as the reticular part of the substantia nigra (SNr), STN, 
and dorsomedial striatum. Additionally, strong projections were observed from the central 
part of the amygdala, the oval nucleus of the bed nuclei of the stria terminalis, hypothalamic 
regions, and the superior colliculus. In contrast to this, GABAergic PPN neurons seemed to 
receive only sparse innervation from basal ganglia structures, whereas strong innervation 
from the superior colliculus, dorsal raphe nuclei, the oval nucleus of the bed nuclei of the 
stria terminalis, hypothalamic regions, and the preoptic area. To our knowledge, no cell-type 
specific tracing studies of cholinergic PPN neurons are available. 
The PPN’s extensive connections with functionally and anatomically diverse brain regions 
and its natural heterogeneity underpin that it is involved in several highly preserved brain 
functions [105, 227]. Projections from the PPN have been implicated in: (1) arousal and 
REM-sleep as a critical component of the ascending reticular arousal system (ARAS) via 
ascending pedunculo-thalamo-cortical pathways [154]; (2) modulation of motor activity over 
descending projections to brainstem motor regions and cortico-striatal circuits [254]; (3) 
generation of rapid responses as a result of integrating sensory input from different 
modalities [105]; and (4) making new action-outcome associations [2, 139]. 
1.4.2 Implications in Parkinson’s disease 
According to the neuropathological staging scheme of Braak, the PPN displays Lewy 
pathology in stage 3 of the disease, thus, the occurrence of LB in the PPN coincides with LB 
pathology in the SNc (see chapter 1.1.3) [30, 31]. Remarkably, despite the neurochemical 
heterogeneity of PPN neurons, the vast majority of aSYN aggregates are found in the 
cholinergic neuronal subpopulation [108, 346]. Additionally, several studies reported severe 
cell loss of cholinergic neurons ranging between 36 and 57% [117, 122, 137, 226, 249]. In 
stark contrast to this, stereological studies estimating degeneration of GABAergic PPN 
neurons reported an average loss 18% compared to 50% of loss of cholinergic PPN neurons 
in the same patients [226]. This suggests that cholinergic neurons are inherently more 
susceptible to the disease process. 
The PPN provides the major source of cholinergic innervation to the thalamus via the 
pedunculo-thalamic pathway. As a consequence, neuroimaging of thalamic cholinergic 
innervation likely reflects the integrity, or, under pathological conditions, the dysfunction of 
PPN cholinergic pedunculo-thalamic efferents. Several studies reported thalamic cholinergic 
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denervation in PD patients implicating PPN cholinergic dysfunction and/or degeneration 
[28, 152, 201]. Additionally, thalamic cholinergic denervation seemed to correlate with the 
occurrence of gait disorders and falls [28, 201]. This finding is further supported by 
neuropathological studies observing a significantly greater reduction of cholinergic PPN 
neurons in PD patients with a history of falls compared to PD patients without falls or 
healthy controls [137]. This underpins the importance of PPN in the modulation of gait and 
locomotion. 
The involvement of the PPN in the disease process and the resulting deafferentation of PPN 
output regions are implicated in the pathophysiology of several motor and non-motor 
symptoms of PD, including gait disorders, sleep disorders such as RBD, and certain cognitive 
deficits [19, 82]. 
1.5 The locus coeruleus-noradrenergic system 
1.5.1 Functional neuroanatomy of the locus coeruleus 
The locus coeruleus (LC) is a small, bilateral nucleus in the rostral pontine tegmentum, 
located in close vicinity to the 4th ventricle [18]. It mainly contains noradrenergic neurons, 
however, recent evidence indicates the existence of local GABAergic neurons [33]. It 
encompasses around 1500 neurons per hemisphere in rodents, and between 10 000 and 
35 000 neurons in humans [24]. The LC-noradrenergic system possesses long, thinly or 
unmyelinated, hyperbranched axons [8]. In spite of the small cell number and owing to its 
extensively ramified axonal arborization, it represents the major source of noradrenaline to 
vast parts of the brain. Its axonal projections form three major pathways innervating various 
regions of the CNS spanning over the whole rostro-caudal extent of the neuroaxis: (1) the 
ascending pathway innervates all areas of the neocortex, midbrain structures (e.g. raphe 
nuclei, superior colliculus), the thalamus (mainly the intralaminar thalamic nuclei), and parts 
of the limbic system such as the amygdala and the hippocampus; (2) the cerebellar pathway 
innervates the deep cerebellar nuclei and the cerebellar cortex; and (3) the descending 
pathway innervates brainstem motor nuclei, such as the dorsal motor nucleus of the vagal 
nerve, and spinal neurons (Fig. 1.8) [298]. Remarkably, the only CNS regions devoid of LC-
noradrenergic innervation are the caudate nucleus, the putamen, the internal and external 
divisions of the globus pallidus, the substantia nigra, and the nucleus accumbens [276]. 
The LC-noradrenergic system not only broadcasts information to wide array of brain regions, 
but it was shown to receive direct input from a just as large variety of structures. Highly 
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advanced rabies viral genetic tracing techniques revealed up to 111 brain regions directly 
innervating LC noradrenergic cells, where 9-15 different brain regions made monosynaptic 
contact with individual LC cells [33, 277]. The LC receives monosynaptic input from 
functionally diverse brain regions: (1) sensory areas, such as brainstem sensory nuclei or the 
dorsal horn neurons of the spinal cord; (2) motor areas, such as the substantia nigra, motor 
cortical areas, or deep cerebellar nuclei; (3) limbic regions, such as the amygdala or the bed 
nuclei of the stria terminalis; (4) brain regions implicated in sleep/arousal regulation, such as 
the periaqueductal gray; (5) autonomic regions, such as the paraventricular hypothalamic 
nucleus; and (5) brain regions implicated in cognitive functions, such as basal forebrain 
structures, and the prefrontal cortex [33, 277].  
LC-noradrenergic neurons possess two distinct modes of chemical transmission: (1) synaptic 
or wiring transmission refers to highly organized connections between neurons, where point-
to-point chemical neurotransmission between two cells takes place; and (2) volume or 
paracrine transmission implicates non-synaptic neurotransmitter release, were the released 
neurotransmitter (so called neuromodulator) diffuses through the interstitial space and 
cerebrospinal fluid, resulting in a diffuse, hormone-like modulation of nearby neuronal as 
well as glial cells [87, 120]. Remarkably, a few studies investigating the proportion of the two 
neurochemical transmission systems in cortical noradrenergic efferents revealed that synaptic 
contacts responsible for wiring neurotransmission were only seen in up to 20% of 
neurotransmitter release sites implicating that cortical noradrenergic neurotransmission relies 
mostly on a non-junctional system [51, 279].  
The LC-noradrenergic system is engaged in several highly preserved brain functions such as 
the regulation of the sleep-wake cycle [301], enhancement of arousal [7, 23], facilitation of 
behavioral adaptions elicited by novel environmental stimuli, modulation of cognitive 
processes such as memory consolidation and –retrieval [265], and controlling autonomic 
functions [329]. LC-noradrenergic neurons display state-dependent activity: they are fully 
quiescent during rapid eye movement (REM) sleep, discharge at low rates during non-REM 
sleep, and at high rates during waking and wakefulness [81, 301]. Their neuronal activity 
closely correlates with the level of behavioral and cortical arousal and cognitive performance 




Figure 1.8 | Neuroanatomy of the LC-noradrenergic efferent pathways and their functions. 
 
Interestingly, the LC noradrenergic fibers do not only make contact with neurons, but also 
with non-neuronal cells and structures by which they exert distinct neuromodulatory effects. 
It was shown that noradrenergic modulation of microglial cells decreases the production of 
pro-inflammatory cytokines thereby exerts anti-inflammatory effects; noradrenergic 
innervation of astroglial cells seems to promote the brain’s metabolic responses to stress; and 
innervation of the blood vessels is implicated in the activity-dependent redistribution of 
cerebral blood volume promoting functional hyperemia in highly active brain regions [17, 
76, 237, 298]. 
1.5.2 Implications in Parkinson’s disease 
A large body of evidence indicates that LB formation of noradrenergic LC neurons antedates 
the occurrence of Lewy pathology in and neurodegeneration of the dopaminergic SNc [30, 
31, 132, 310]. According to the Braak staging hypothesis, the LC is affected in stage 2, just 
after the affection of the dorsal motor nucleus of the vagal nerve and the OB (see chapter 
1.1.3) [30, 31]. Studies of neurodegenerative LC changes during the disease have reported 21 
to 93% of neuronal cell loss in advanced PD stages, however, data of early PD stages are 
lacking [25, 41, 94, 108, 121, 221]. Neurodegeneration is usually distributed homogeneously 
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over the rostro-caudal extent of the LC, but in PD patients with dementia, the rostral 
portions of the LC display more severe cell loss [41]. Remarkably, although noradrenergic 
LC neurons display Lewy pathology earlier in the disease process than dopaminergic SNc 
neurons, they generally show less neurodegeneration than SNc neurons [41, 108, 109]. It is 
therefore tempting to speculate that LC neurons might have inherent properties which 
render them particularly vulnerable to pathophysiological processes underlying disease 
initiation, however, might have intrinsic features rendering them partially resilient against 
pathologic processes underlying disease progression. 
Neuromelanin (NM)-sensitive magnetic resonance imaging (NM-MRI) allows the in vivo 
visualization of NM-content in neuromelanized brain nuclei, such as the LC and the SNc. 
Studies pursued in early and advanced stage PD patients observed significantly attenuated 
signal intensities in the LC region implicating loss of NM-containing LC neurons, a 
significant decrease of intracellular NM-content, or both [39, 199, 209, 267, 278]. Moreover, 
a study investigating NM-MRI signals in the LC region of patients with RBD, the most 
specific prodromal symptom of PD has revealed significantly diminished NM signal 
intensities in the LC region, indicating that the LC is already affected in prodromal PD [68]. 
The involvement of the LC in the disease process and the resulting noradrenergic 
deafferentation of LC output regions are implicated in the pathophysiology of several NMS 
of PD such as depression, anxiety, apathy, fatigue, cognitive impairment and dementia [61, 
84, 240, 347]. 
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2 Aims of the study 
The aim of the present study was twofold.  
Firstly, we wanted to investigate whether the selective vulnerability pattern of PPN neuronal 
subpopulations seen in human PD also translates into an animal model. Therefore, we aimed 
to establish a novel PD mouse model by targeted injection of PFF’s into the PPN and analyze 
the induced local pathological alterations in a timely manner. The specific scientific questions 
were the following: 
1. Does the local injection of PFF’s induce aggregate formation in the PPN? 
2. Does injection of aSYN PFF’s induce α-synucleinopathy in all three neuronal subtypes, 
i.e. are cholinergic, GABAergic and glutamatergic neurons similarly affected? 
3. Do all three neuronal subtypes degenerate in a comparable manner? 
4. Does the local induction of α-synucleinopathy induce reactive microgliosis? 
Currently, the two most popular animal models in the PD field rely on the focal induction 
of α-synucleinopathy either by targeted inoculation of PFF’s or by loco-regional injection of 
aSYN-overexpressing viral vectors. Therefore, in a second set of experiments, we aimed to 
compare the brain-wide propagation pattern of two focally induced α-synucleinopathy 
mouse models, in which the initiation of the aSYN aggregation process and the site of α-
synucleinopathy induction was different. To compare the aSYN propagation patterns in 
these two models, the following scientific questions were raised: 
1. How does the brain-wide pattern of propagation look like in the different models? 
2. Is the aSYN signal localized predominantly in axonal processes or perikarya? 
3. Can a cell-to-cell transmission of aSYN be proven in the models? 
4. What are the predominant aSYN species in distant brain regions? 
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3 Materials and methods 
3.1 Experimental design 
This study consists of two major parts.  
In the first part of the study (Fig. 2.1A), PFF or monomeric aSYN (control) induced 
pathological changes were evaluated in a mouse model of PD. Therefore, PFF’s or 
monomeric aSYN (control) were injected in the left PPN of wild-type mice. Subsequently, 
animals were consecutively sacrificed with transcardial perfusion 1, 6, and 12 weeks post-
injection (wpi) for immunohistochemical analysis of: (1) locally induced pathology to 
delineate selective cellular vulnerability; and (2) brain-wide propagation of the PFF-induced 
pathology. 
In the second part of the study (Fig. 2.1B), adeno-associated viral vectors containing the gene 
of human mutant A53T-aSYN or Luciferase (control) were injected into the right LC region 
of wild-type mice. Animals were sacrificed with transcardial perfusion 1, 3, 6, and 9 wpi for 
immunohistochemical analysis of brain-wide propagation of the locally induced pathology. 
 
Figure 2.1 | Experimental design 
A. Experimental design and schematic illustration of PFF injection into the left PPN of the mouse. Animals 
were consecutively sacrificed after 1, 6, and 12 weeks for immunohistochemical evaluation. 
B. Experimental design and schematic depicting viral vector injection into the right LC of mouse. Animals 
were consecutively sacrificed after 1, 3, 6, and 9 weeks for immunohistochemical evaluation. 
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3.2 Materials and chemicals 
3.2.1 Expendable supplies and materials 
Bepanthen creme Bayer 
Bepanthen® eye ointment Bayer 
Combitips Eppendorf 
Costar® 12-well Clear TC-treated Well plates Corning Incorporated 
Cover slips Menzel-Gläser GmbH 
CryoPure tubes Sarstedt 
Ethibond ExcelTM 3-0 USP,  19 mm 3/8c Ethicon 
Eukitt® Quick-hardening Mounting Medium Sigma-Aldrich 
Gloves (size M, powder free) NOBA GmbH 
Microscope glass slides Menzel-Gläser GmbH 
Nanofil stainless needle, 33G World Precision Instruments (WPI) 
Nanofil syringe World Precision Instruments (WPI) 
NetwellTM 12-well Carrier Kit for 15 mm Inserts Corning Incorporated 
Pasteur pipettes Sarstedt 
Pipette tips (10 μl, 100 μl, and 1000 μl) Eppendorf AG 
Pipettes (5 ml, 10 ml, 25 ml) Sarstedt 
ProLong Diamond Antifade Mountant Thermofisher Scientific 
Sterilin 100 mm Square Petri Dishes Bibby Sterilin 
Surgical instruments (scissors, forceps, etc.) Bochem Instrumente 
Tissue freezing medium Leica 
 
3.2.2 Stereotactic operations, perfusion, and brain processing 
AAV1/2-CMV/CBA-A53T-aSYN vector GeneDetect 
AAV1/2-CMV/CBA-Luciferase GeneDetect 
Biotin tagged aSYN Monomers Provided by Ted M. Dawson (John Hopkins University) 
Carprophen Zoetis 
Glycerol (99.5+%) Sigma-Aldrich  
Ketamin Intervet 
Lidocain 5% Serumwerk Bernburg 
Na2HPO4 Merck Millipore 
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NaCl Sigma-Aldrich 
NaH2PO4 Merck Millipore 
Paraformaldehyde (PFA) Roth 
Preformed aSYN fibrils (PFF’s) Provided by Ted Dawson (John Hopkins University) 
Xylazine (2%) Bayer 
Sterile NaCl (0.9%) solution Braun 
Sucrose (99.95%) Sigma-Aldrich 
 
3.2.3 Immunohistochemistry 
3.2.3.1 Solutions, chemicals, and kits 
3,3’-diaminobenzidine (DAB) Serva 
DAPI Sigma-Aldrich 
Ethanol absolute (>99.8%) Otto Fischar GmbH & Co. 
H2O2 (30%) Merck Millipore 
Methanol (99.8%) Sigma-Aldrich 
Na-hypochlorite Roth 
Normal donkey serum Millipore 
Proteinase K Invitrogen 
SK-4700 SG Peroxidase Kit Vector Laboratories 
Triton X-100 Sigma-Aldrich 
Vectastain® Elite® ABC HRP Kit Vector Laboratories 
Xylene J.T.Baker 
3.2.3.2 Primary antibodies 
Antigen Host Cat. No. Manufacturer Dilution 
Alpha-synuclein (p-S129) Rabbit ab51253 Abcam 1:2000 
Choline Acetyltransferase (ChAT) Goat AB144P Merck Millipore 1:100 
IbA1 Rabbit 019-19741 Wako 1:500 
Neuron N (NeuN) Mouse MAB377 Merck Millipore 1:1000 
SQSTM1/p62 Mouse ab56416 Abcam 1:2000 
Human α-synuclein (Syn211) Mouse AH90261 ThermoFisher Scientific 1:1000 
Luciferase Goat NB100-1677 Novus Biologicals 1:250 
MAP2 Chicken ab5392 Abcam 1:2000 
Ubiquitin (Ubi-1) Mouse ab7254 Abcam 1:2000 
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3.2.3.3 Secondary antibodies 
Antigen Host Cat. No. Manufacturer Dilution 
Anti-chicken Cy3 Donkey 703-165-155 Jackson ImmunoResearch 1:1000 
Anti-goat AlexaFluor405 Donkey ab175664 Abcam 1:1000 
Anti-goat AlexaFluor488 Donkey A-11055 Invitrogen 1:1000 
Anti-goat Cy3 Donkey 705-165-147 Jackson ImmunoResearch 1:1000 
Anti-mouse AlexaFluor488 Donkey A-2102 Invitrogen 1:1000 
Anti-mouse Cy3 Donkey 715-165-150 Jackson ImmunoResearch 1:1000 
Biotinylated anti-mouse Donkey 715-065-151 Jackson ImmunoResearch 1:1000 
Biotinylated anti-rabbit Donkey 711-065-152 Jackson ImmunoResearch 1:1000 
Biotinylated anti-goat Donkey 705-065-147 Jackson ImmunoResearch 1:1000 
Streptavidine AlexaFluor647 Donkey 016-600-084 Jackson ImmunoResearch 1:1000 
 
3.2.4 Buffers and solutions 















Adjust to pH 7.4 with NaOH (30%) and filter 
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4% paraformaldehyde working solution (500 ml): H2O dest. (heat up to 60°C) 
PFA (add while stirring) 
30% NaOH 





If needed, adjust pH to 7.4 with NaOH (30%) 
 
30% sucrose working solution (100 ml): Sucrose 




DAB stock solution (5 mg/ml, 50 ml): DAB 
H2O dest. 





DAB working solution (40 ml): 0.1 M PB 













ABC-Kit working solution (10 ml): 0.1 M PB 
Avidin (reagent A) 














Materials and methods 
37 
3.2.5 Equipment and software 
3.2.5.1 Equipment 
Equipment Model Manufacturer 
Color camera Axiocam 506 Zeiss 
Confocal microscope TCS SP8 Leica 
Cryostat microtome CM3050S Leica 
Digital Rat Stereotaxic Instrument 51900 Stoelting 
Electric driller Micromot 40/E+, NG 5/E Proxxon 
Homeothermic Blanket System 50305 Stoelting 
Micro Syringe Pump Controller Micro4TM, UMC4 World Precision Instruments (WPI) 
Microscope AxioImager M2 Zeiss 
Monochrome camera C11440, Orca-flash4.0 LT Hamamatsu 
Mouse Adaptor 51624 Stoelting 
Shaker Polymax 2040 Heidolph 
Shaker Unimax 1010 Heidolph 
Shaker IKA-VIBRAX-VXR Bachofer Laboratoriumsgeräte 
Shaking water bath GFL 1083 Kobe 
Variable-speed tubing pump Masterflex C/L Novodirect 
 
3.2.5.1 Software 
Adobe Illustrator v21.1 Adobe Systems 
FIJI http://rsbweb.nih.gov/ij/ 
GraphPad Prism Software v7 GraphPad Software, La Jolla, California, USA 
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3.2.6 Animals and animal husbandry 
For the viral vector injections, a total number of 48 C57Bl/6 mice (Charles River, Sulzfeld, 
Germany), 8 weeks old at the beginning of the experiment, were used. Animals were housed 
in individually ventilated cages with ad libitum access to food and water under a 12 h/12 h 
light-dark cycle.  All procedures performed were in accordance with the ethical standards 
and approved by the appropriate institutional governmental agency (Regierungspräsidium 
Gießen, Germany). 
For the PFF and monomeric aSYN injections, a total number of 14 C57Bl/6J mice (Stock 
JAX:000664, Jackson Laboratory, USA), 8 weeks old at the beginning of the experiment, 
were used. Animals were housed in standard cages with ad libitum access to food and water 
under a 12 h/12 h light-dark cycle. All experimental procedures performed were in 
accordance with ethical standards (NIH Guide for the Care and Use of Laboratory Animals) 
and approved by the Northwestern University Animal Care and Use Committee. 
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3.4 Methods 
3.4.1 Production of mouse full length aSYN pre-formed fibrils 
PFF’s were produced at the John Hopkins University School of Medicine, Baltimore, USA 
according to protocols published elsewhere [228, 321], and provided by Ted M. Dawson. 
Briefly, thawed purified recombinant monomeric mouse full-length aSYN was centrifuged 
at 100 000g at 4 °C for 60 minutes to free the solution of any pelleted (aggregated) aSYN. 
The resulting supernatant was then pipetted into a sterile Eppendorf and diluted to a final 
protein concentration of 5 mg/ml. The Eppendorf was then placed into an Eppendorf 
Thermomixer R and shaken at 1 000 r.p.m. at 37 °C for 7 days to induce aSYN fibril 
formation. Next, aSYN PFF’s were sonicated with 60 pulses at 10% power to fragment large 
fibrils into toxic, small aSYN seeds. To avoid repeated freeze-thaw cycles, PFF’s were 
aliquoted and stored at -80 °C until use. 
3.4.2 Unilateral microinjection of viral vectors or PFF’s 
Mice receiving PFF or monomeric aSYN injections into the left PPN were operated at the 
Northwestern University Chicago, USA by Martin T. Henrich. Mice receiving a viral vector 
injection into the right LC were operated by Fanni F. Geibl at the Philipps University 
Marburg, Germany. 
For unilateral stereotactic injection into the LC, mice were deeply anesthetized with 
intraperitoneal injection of a mixture of ketamine (100 mg/kg bodyweight) and xylazine (5-
10 m/kg bodyweight) diluted in sterile physiologic saline (0.9% NaCl), whereas for the 
injection into the PPN, mice were anesthetized with isoflurane. The depth of general 
anesthesia was assessed by testing the toe pinch reflex. When the level of surgical anesthesia 
was achieved, the head of the mouse was shaved and subsequently fixed in the stereotactic 
frame so that the surface of the skull paralleled the horizontal plane. The skin of the head 
was then opened sagitally in the median line over 1-1.5 cm and Bregma2 and Lambda3 were 
identified (Fig. 3.1A-C). Taking Bregma as a reference point, the following coordinates were 
used to localize the LC or the PPN (Fig. 3.1D,E): 
Axis Coordinates LC Coordinates PPN 
Antero-posterior ‒5.4  ‒ 4.6 
Medio-lateral ‒0.9  +1.15 
Dorso-ventral ‒3.65  ‒3.65  
                                                 
2 Intersection of the coronal and sagittal sutures. 
3 Intersection of the sagittal and lambdoid sutures. 
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Subsequently, a small hole with 500-600 μm diameter was drilled into the skull with the help 
of an electric driller until the dura mater was exposed.  
The injection of the viral vectors was performed using a microsyringe. A volume of 1.25 μl 
of rAAV-CMV-A53T-aSYN or rAAV-CMV-Luc was injected into the right LC with a 
velocity of 125 nl/min. The needle was kept for an additional 5 minutes in place after the 
injection to reduce efflux of the viral vector into the needle tract. The needle was thereafter 
retracted at a slow pace (1 mm/min).  
Injection of the PFF’s was performed using a glass pipette, pulled on a P-97 pipette puller. 
A volume of 500 nl of aSYN PFF’s or monomeric aSYN was injected into the left PPN with 
a velocity of 100 nl/min. The glass pipette was kept for an additional 5 minutes in place after 
the injection to reduce PFF/monomeric aSYN efflux into the needle tract. The glass pipette 
was thereafter retracted at a slow pace (1 mm/min). 
After successful stereotactic injection, the skin of the head was sutured with 4 to 5 individual 
stitches. The mouse was then warmed with an infrared lamp until awakening. 
 
Figure 3.1 | Stereotactic operation 
A. Surface of the mouse skull after incision of the skin. The different bone plates and their sutures are well 
identifiable. 
B. Sutures of the mouse skull and identification of Bregma and Lambda reference points. a Bregma; b frontal 
or coronal suture; c sagittal suture; d lambda; e lambdoidal or occipital suture; f interaural line. 
C. Mouse brain in the dorsal view. 1 olfactory bulbs; 2 cerebrum and cerebral neocortex; 3 fissura 
longitudinalis cerebri; 4 cerebellum and cerebellar cortex; 5 spinal cord. 
D. Location of stereotactic injection of PFF’s or monomeric aSYN into the left PPN in the sagittal (left) and 
coronal (right) view. Abbreviations: AP, antero-posterior axis; ML, medio-lateral axis; DV, dorso-ventral 
axis. 
E. Location of stereotactic injection of viral vectors into the right LC in the sagittal (left) and coronal (right) 
view. Abbreviations: AP, antero-posterior axis; ML, medio-lateral axis; DV, dorso-ventral axis. 
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3.4.3 Transcardial perfusion, post-fixation, and microtomy 
For reliable immunohistochemical analysis, brains have to be devoid of blood and fixed in a 
life-like state. As the intact brain (and mostly other intact organs as well) are too big for 
immersion fixation as the fixative (in our case 4% PFA) does not penetrate the tissue 
homogeneously, brains have to be fixed in situ by transcardial perfusion with 4% PFA [88]. 
For this purpose, mice were deeply anesthetized by intraperitoneal injection of a mixture of 
ketamine (100 mg/kg bodyweight) and xylazine (5-10 m/kg bodyweight) diluted in sterile 
physiologic saline (0.9% NaCl). The depth of the general anesthesia was assessed by testing 
the toe pinch reflex. Mice were subsequently fixed on their backs, and the thorax was opened 
with scissors to reveal a good view on the heart. A small incision was made in the right atrium 
and thereafter the left ventricle was punctured around the apex cordis with a needle 
connected to a perfusion pump. First, the blood was washed out of the vessels with ice-cold 
PBS solution for 5 to 10 minutes (15 ml/min rate, ~100 ml PBS), followed by ice-cold 4% 
PFA for 5 to 10 minutes to fix the brain in situ (15 ml/min rate, ~100 ml PFA). Subsequently, 
the brains were carefully removed and post-fixed in 4% PFA for 2-3 days and then 
transferred to 30% sucrose solution at 4 °C for 2-3 days for dehydration and cryoprotection. 
Brains were then frozen on dry ice and stored in -80°C until sectioning. 
For sectioning, whole brains were embedded in tissue freezing medium and cut from the 
olfactory bulb to the spinal cord into 30 μm consecutive coronal sections at ‒ 20 °C using a 
cryostat-microtome. A punctual mark was placed with a needle on the right side of the brains 
for later identification of the injected and non-injected sides. Sections were collected into 
eight equally spaced (240 μm) series and kept in antifreeze solution at 4 °C until further 
processing.  
 
3.4.4 Immunohistochemistry – indirect immunofluorescence staining 
For indirect immunofluorescence stainings, 30 μm thin free-floating sections were first 
washed four times five minutes in 0.1 M PB solution to remove the cryoprotectant. 
Thereafter, sections were blocked in 10% normal donkey serum (NDS) in PBT for one hour 
on a shaker at room temperature followed by overnight incubation at 4 °C with primary 
antibodies at the respective dilutions (see 3.2.3.2) in the same blocking solution. On the 
second day, sections were washed three times five minutes in 0.1 PB and one time five 
minutes in PBT, followed by incubation with fluorophore-conjugated, species-specific 
secondary antibodies at the respective dilutions (see 3.2.3.3) in the same blocking solution 
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for two hours at room temperature. Subsequently, sections were washed two times five 
minutes in PBT, followed by incubation with DAPI at a concentration of 0.5 μg/ml in 0.1 M 
PB solution for 10 minutes. Sections were then washed for three times five minutes in PBT 
before mounting them on glass slides and covering with ProLong Diamond Antifade 
Mountant. 
Exceptions from this general protocol were made for staining microglial cells (IbA1) and 
phosphorylated aSYN (p-aSYN), where following the overnight incubation with the 
respective primary antibodies (see 3.2.3.2), sections were incubated for one hour in blocking 
solution with biotinylated, species-specific secondary antibodies directed against the primary 
antibody for IbA1 or p-aSYN (see 3.2.3.3). Sections were thereafter washed three times five 
minutes in PBT, followed by incubation with fluorophore-conjugated streptavidine and 
fluorophore-conjugated species-specific secondary antibodies at the respective dilutions (see 
3.2.3.3) for two hours at room temperature. The following steps were identical with the 
general protocol described above. 
 
3.4.5 Immunohistochemistry – DAB and SK-4700 double staining 
For stereological analysis of cholinergic and non-cholinergic neurons of the PPN, an 
immunohistochemical double staining visualizing choline acetyltransferase (ChAT, rate-
limiting enzyme in acetylcholine production and therefore marker of cholinergic neurons) 
and Neuron N (NeuN, pan-neuronal nuclear antigen, general marker for neuronal cells) was 
used. Therefore, 30 μm thin free-floating coronal sections containing the PPN region were 
washed four times five minutes in 0.1 M PB solution to remove cryoprotectant. Thereafter, 
endogenous peroxidase activity was quenched with peroxidase blocking solution (see 3.2.4) 
for fifteen minutes, followed by four times five minutes washing in 0.1 M PB solution. 
Sections were then blocked in 10% NDS in PBT for one hour at room temperature and 
incubated overnight at 4 °C with the primary antibody against NeuN (Merck Millipore, 
MAB377, 1:1000). On the second day, sections were washed four times five minutes in 0.1 
M PB solution, followed by a one-hour incubation at room temperature with biotinylated 
anti-mouse secondary antibody (Jackson Immunoresearch, 715-065-151, 1:1000). This was 
followed by a one-hour incubation at room temperature in ABC-Kit working solution (see 
3.2.4). Sections were then washed four times five minutes in 0.1 M PB-solution to remove 
unbound ABC-Kit solution and thereafter incubated for two minutes in DAB working 
solution (see 3.2.4) to induce the chromogenic reaction. This step, due to the high toxicity 
of DAB, was strictly performed under a hood. Sections were thereafter washed in 0.1 M PB 
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four times for five minutes and blocked in 10% NDS in PBT solution. Sections were then 
incubated overnight at 4 °C with a primary antibody directed against ChAT (Merck Millipore, 
AB144P, 1:100). On the third day, sections were washed four times five minutes in 0.1 M 
PB solution and incubated with a biotinylated anti-goat secondary antibody (Jackson 
ImmunoResearch, 705-065-147, 1:1000) for one hour at room temperature followed by a 
one-hour incubation in ABC-Kit working solution (see 3.2.4) at room temperature. Sections 
were then washed four times five minutes in 0.1 M PB solution and thereafter incubated for 
two minutes in SK-4700 working solution under the hood. Remaining SK-4700 solution was 
then removed in a four times five minutes washing step. Sections were then mounted on 
gelatinized glass slides and left to dry for two hours. This was followed by immersion of the 
tissue through a series of ethanol solutions of increasing concentrations (70%, 96%, 100%) 
for stepwise dehydration. The sections were finally passed twice through 100% xylene and 
coverslipped with Eukitt Quick-hardening Mounting Medium. 
As both chromogens (DAB and SK-4700) are highly toxic, everything that was potentially 
contaminated with the chromogens (e.g. pipette tips, plates, gloves, beakers) was neutralized 
in 10% sodium hypochlorite (NaOCl) solution overnight and discarded in a biohazard box. 
 
3.4.6 Proteinase K enzymatic digestion 
One of the pathological hallmarks of PD is the intracellular accumulation of LBs and LNs 
consisting mainly of aSYN. A major characteristic and established marker of the aggregated 
state of aSYN is Proteinase K (PK) resistance [160, 203]. PK is a serine protease with a broad 
substrate specificity degrading most of the proteins, including aSYN in their native state. PK 
enzymatic digestion was performed as follows. 
Sections were washed three times five minutes in 0.1 M PB solution and once for five 
minutes in PBT. Thereafter, sections were digested for ten minutes in 12 μg/ml PK diluted 
in PBT at 65 °C in a shaking water bath. Sections were then washed four times five minutes 
in 0.1 M PB solution at room temperature to remove PK. To visualize the PK-resistant 
(remaining) aSYN aggregates, the tissue was double stained for human aSYN, p-aSYN, p62, 
or Luc in combination with TH or ChAT (see 3.2.3.2) with the immunofluorescence staining 
protocol described above (see 3.4.4). The stainings for TH and ChAT served as controls: in 
case of complete digestion, immunoreactivity of the neurotransmitter systems were 
completely absent in the tissue. Sections with visible TH or ChAT immunoreactivity 
indicating incomplete digestion were excluded from the analysis.  
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3.4.7 Stereology 
Unbiased stereology is a widely used method for the estimation of quantitative parameters 
of three-dimensional structures (brain regions, nuclei) from two-dimensional materials 
(planar histological tissue sections) [141, 272].  
The analysis was performed using the optical fractionator workflow of the StereoInvestigator 
Software (MBF Biosciences, version 9). This method is based on the unbiased estimation of 
population number (in this case neuronal number) in the whole volume by unbiased analysis 
of a known fraction of volume. To achieve a uniform systematic sampling of the region of 
interest (ROI, the PPN), a known fraction of the serial sections containing the ROI with a 
known section thickness (z-axis) and known sectional area randomly assigned by the software 
(x-, and y-axes) was counted and the extrapolation of total neuronal number of the ROI was 
performed by the workflow. 
The quantification of cholinergic and non-cholinergic neurons of the PPN was performed 
with ChAT and NeuN double stained sections (see 3.4.5) of five pre-defined Bregma 
coordinates (‒4.24, ‒4.48, ‒4.72, ‒4.84, ‒4.96) (Fig. 3.2). The contours of the ROI were 
drawn according to the cytoarchitectonic distribution of cholinergic (ChAT-positive) 
neurons. ChAT- and NeuN-positive cells (cholinergic PPN neurons) and ChAT-negative but 
NeuN-positive (non-cholinergic neurons) were counted separately in the same sections. 
Parameters used for the counting were: grid size 100 × 100 μm, counting frame 85 × 85 μm, 
and 2 μm guard zones. Analysis was performed at 40× magnification. The investigator was 
blinded to treatment (PFF vs. monomeric aSYN), time-point, and injection side. 
 
Figure 3.2 | Coronal sections of the PPN included into stereological assessment  
Stereological quantification was performed of five distinct coronal serial sections of defined Bregma 
coordinates containing the whole rostro-caudal extent of the PPN (red). The contour of ROI was drawn 
according to the cytoarchitectonic distribution of ChAT-positive neurons. ChAT- and NeuN-positive and 
ChAT-negative but NeuN-positive cells were counted separately in the same sections of every animal. 
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3.4.8 Whole-brain analysis of p-aSYN pathology in the PFF model 
For the whole brain analysis of p-aSYN pathology progression, equidistant sections with an 
interslice distance of 240 μm spanning the complete rostro-caudal extent of the mouse brain 
were stained against p-aSYN and DAPI following the immunofluorescence staining protocol 
described above (see 3.4.4). A semiquantitative grading system for p-aSYN neurite and soma 
pathology ranging from 0 to 4 was established. Neurite (N) and soma (S) pathology was 
graded separately as follows: N1 sparse pathology (very few neurites), N2 mild pathology 
(more neurites, but large areas uncovered), N3 dense pathology (brain regions covered, but 
places spared), N4 very dense pathology (brain region densely covered; and S1 sparse 
pathology (1-3 soma), S2 mild pathology (4 or more soma, but large areas uncovered), S3 
dense pathology (many aggregates, but places spared), S4 very dense pathology (brain region 
densely covered by aggregates) (Fig. 3.3). 
 
Figure 3.3 | Semiquantitative grading system for the whole-brain analysis of p-aSYN neurite and soma 
pathology 
A. Template images used to assess the degree of p-aSYN neurite pathology (N0-4). The grading system 
ranged from 0 [very few neurites in brain region] to 4 [brain region densely covered by p-aSYN neurite 
pathology]. 
B. Template images used to assess the degree of p-aSYN soma pathology (S0-4). The grading system ranged 
from 0 [1-3 soma in brain region] to 4 [brain region densely covered by aggregates]. 
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First, stained sections were scanned with the 10× objective lens of the AxioImager M2 
microscope using the Virtual Tissue (slide scanning) workflow of the StereoInvestigator Software 
(MBF Biosciences, version 9). Thereafter, each tissue section was matched to the 
corresponding atlas image of the coronal reference atlas of the mouse brain by the Allen 
Institute, USA [3]. The degree of p-aSYN pathology was graded in every brain region using 
the template images of the grading system (Fig. 3.3). Brain regions were identified based on 
the DAPI signal and tissue autofluorescence. Mean score values were calculated for every 
brain region, treatment group (PFF vs. monomeric aSYN) and time-point. The investigator 
was blinded to treatment (PFF vs. monomeric aSYN) and time-point. Color coded heatmaps 
were generated with the Adobe Illustrator program.  
 
3.4.9 Whole-brain analysis of human aSYN propagation in the rAAV model 
For the whole-brain quantification of human aSYN propagation, coronal sections of pre-
defined Bregma coordinates (+4.28, +2.86, +1.18, +0.38, ‒3.16, ‒7.56) covering the 
complete rostro-caudal extent of the brain were stained against human aSYN, or Luc in 
combination with DAPI following the immunofluorescence staining protocol described 
above (see 3.4.4). A semiquantitative grading system from 0 to 4 was established and template 
images for later assessment of the degree of aSYN transport were acquired.  
First, stained sections were scanned with the 10× objective lens of the AxioImager M2 
microscope using the Virtual Tissue (slide scanning) workflow of the StereoInvestigator Software 
(MBF Biosciences, version 9). Thereafter, each tissue section was matched to the 
corresponding atlas image of the coronal reference atlas of the mouse brain by the Allen 
Institute, USA [3]. The degree of human aSYN pathology/transport was assessed in every 
brain region using the template images of the grading system as follows: 0, no positive axons; 
1, sparse (few positive axons); 2, mild (more positive axons); 3, moderate (many positive 
axons, covering almost the complete brain region); and 4, severe pathology (large number of 
positive axons densely covering the complete brain region). Brain regions were identified 
based on the DAPI signal and tissue autofluorescence. Mean score values were calculated 
for every brain region, treatment group (A53T-aSYN vs. Luc) and time-point. The 
investigator was blinded to treatment and time-point. Color coded heatmaps were generated 
with the Adobe Illustrator program. 
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3.4.10 Quantification of reactive microgliosis 
For the analysis of reactive microgliosis in the PPN region, coronal sections containing the 
whole rostro-caudal extent of the PPN were stained against ionized calcium binding adaptor 
molecule 1 (IbA1; microglial marker), ChAT, and DAPI following the immunofluorescence 
staining protocol described above (see 3.4.4). The quantification of the microgliosis was 
performed based on previously published protocols [220, 252]. First, images of the PPN 
region were captured using the 10× objective lens of the AxioImager M2 microscope (Zeiss, 
Germany). Images were then loaded into FIJI software [271], the IbA1 channel was isolated 
and the mean background of this channel was subtracted. The remaining background was 
measured, multiplied by four, and then this value was set as a threshold. All pixels with an 
intensity value higher than this threshold were interpreted as positive IbA1-signal and all 
pixels under this threshold value were considered as background labeling. The PPN region 
was outlined based on the cytoarchitectonic distribution of ChAT-positive cells using the 
ChAT-channel of the composite pictures and the IbA1-positive pixel count was quantified. 
This value was then normalized to the total pixel count of the sampled area. The investigator 
was blinded to treatment (PFF vs. monomeric aSYN), time-point, and injection side. For the 
analysis, the exact same five sections of pre-defined Bregma coordinates (‒4.24, ‒4.48, ‒4.72, 
‒4.84, ‒4.96) were used (Fig. 3.2). 
 
3.4.11 Imaging 
Fluorescent images were acquired with an AxioImager M2 microscope (Zeiss) equipped with 
an ORCA-Flash4.0 LT CMOS camera (Hamamatsu C11440-42 U). For confocal images, a 
TCS SP8 microscope (Leica) was used. Images were post-processed with FIJI image software 
to enhance signal-to-noise. 
Brightfield images were acquired using an AxioImager M2 microscope (Zeiss) equipped with 
an Axiocam 506 color camera (Zeiss).  
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3.4.12 Statistical methods 
All data were analyzed using GraphPad Prism (version 7.0 GraphPad Software, USA), Fiji 
[271], or Microsoft Excel 2016. In all experiments, sample size was based on prior studies 
using similar techniques and no statistical methods were used to predetermine sample size. 
Column bar graphs display mean and whiskers represent SD. Whisker plots show median, 
lower and upper quartiles and whiskers represent minimum and maximum of the data. 
Statistical significance of differences between two groups was analyzed by single or multiple 
Student’s t-Tests and corrected with Holm-Sidak method for multiple testing. Differences 
between multiple groups were assessed by one-way or two-way ANOVA followed by 
Tukey’s or Dunnett’s multiple comparisons test. To calculate correlations, scatterplots and 
performed linear regression analysis was performed. Differences were considered significant 
at P < 0.05. Distribution of the data was assumed to be normal, but this was not formally 
tested. Significance indicators were kept constant in all figures (*P < 0.05, ** P < 0.01, *** 
P < 0.001) and exact P values are shown in the individual figure legends. All figures were 





4.1 The PFF model of Parkinson’s disease 
4.1.1 Experimental design 
In the PFF mouse model of prodromal PD, we wanted to investigate the preferential 
vulnerability pattern of PPN neurons and the brain-wide propagation pattern of a focally 
induced α-synucleinopathy. Therefore, we injected murine aSYN PFF’s unilaterally into the 
left PPN region of wild-type mice (Fig. 4.1A). As a control, monomeric murine aSYN was 
injected. Animals were consecutively sacrificed after 1, 6, and 12 wpi and local and brain-
wide pathological patterns were investigated. 
 
4.1.2 PFF’s induced aggregate formation in the PPN region as soon as 1 wpi 
Previous studies have proposed that murine aSYN PFF’s possess prion-like properties: they 
act as seeds and thereby induce the self-perpetuating aggregation of primarily soluble 
endogenous aSYN when added to neuronal cell cultures or injected into the murine brain 
[179, 183, 189, 241]. To test whether local PFF injection into the left PPN resulted in 
aggregate formation in our mouse model, we stained brain sections containing the whole 
PPN region against phosphorylated aSYN (p-aSYN), an established marker for α-
synucleinopathy in human PD brains and murine PD models [85, 116, 179, 241]. 
 
Figure 4.1 | PFF injection into the PPN induces aggregate formation. 
A. Schematic depicting strategy for aSYN PFF injections and assessment of pathology. 
B. Representative image showing aggregate formation in the PPN of PFF injected mice 1, 6, and 12 wpi. No 
aggregate formation was detected in monomeric aSYN injected animals. Scale bar, 250 μm 
C. High magnification confocal images of p-aSYN-positive aggregates. Two types of aggregates could be 
distinguished: 1) large perinuclear inclusion bodies (arrows); and 2) smaller, filamentous aggregates 




Our data revealed that injection of PFF’s resulted in robust p-aSYN-positive aggregate 
formation in neurons of the left PPN (Fig. 4.1B). Accumulation of aggregates was 
progressive with first inclusions being observable as soon as 1 wpi. With high magnification 
confocal microscopy, two types of aggregates could be distinguished: (1) large perinuclear 
inclusion bodies (Fig. 4.1C, arrows); and (2) smaller, filamentous p-aSYN-positive aggregates 
in axons or neurites (Fig. 4.1C, arrowheads). The aggregates detected in our PFF animal 
model were highly reminiscent of LBs/LNs found in postmortem human brains. 
Interestingly, the inclusion bodies were not homogeneously distributed over the rostro-
caudal extent of the PPN, but rather showed a gradient with p-aSYN-positive aggregates 
being significantly more abundant in the caudal PPN region (Fig. 4.2B). This distribution 
pattern highly resembled the gradient of cholinergic PPN neurons (Fig. 4.2A). No aggregate 
formation was detected in monomeric aSYN injected animals (Fig. 4.1B). 
 
Figure 4.2 | Rostro-caudal distribution of p-aSYN 
harboring neurons following PFF injection. 
A. Representative sagittal image of the cholinergic PPN of a 
wild-type mouse depicting the rostro-caudal distribution of 
ChAT-positive PPN neurons (magenta, n = 3). Scale bar, 
250 μm. 
B. Distribution of p-aSYN-positive aggregate harboring PPN 
neurons over the rostro-caudal extent of the PPN (blue, n= 
4 for 6 wpi; n = 5 for 12 wpi). Aggregates were counted over 
the whole PPN region from Bregma –4.0 mm to Bregma –
5.0 mm. Afterwards, aggregate count within the respective 
Bregma ranges was normalized to the total aggregate count. 
 
4.1.3 p-aSYN-positive aggregates are PK resistant and p62-positive 
Major hallmarks of LBs and LNs in PD are resistance to protease digestion (PK resistance) 
and SQSTM1/p62-positivity. Former is an indicator of the accumulation of insoluble 
proteinaceous aggregates, whereas latter implicates the dysregulation of the autophagic 
pathway, a common pathogenic event in neurodegenerative proteinopathies [156, 203, 245]. 
To test whether the aggregates found in our PFF mouse model share these characteristic 
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features with human LBs/LNs, we performed PK digestion and subsequently stained the 
sections for p-aSYN, p62, and ChAT.  
PFF, but not monomeric aSYN injected mice showed accumulation of PK resistant and p-
aSYN- and p62-positive inclusion bodies starting 6 wpi (Fig. 4.3). Aggregates were not 
restricted to the ipsilateral side but were also abundant in the contralateral PPN implicating 
that the propagation of the α-synucleinopathy to distant brain regions also results in the 
formation of PK-resistant aggregates (data not shown). 
 
Figure 4.3 | PFF-induced aggregates are PK 
resistant and p62-positive. 
Representative images of p-aSYN- and p62-
positive aggregates after PK digestion (upper row, 
+PK), or without digestion (lower row, Ø PK). 
Inclusion bodies found in the injected PPN 
region are PK resistant. Scale bar, 25 μm. 
 
4.1.4 Cholinergic PPN neurons bear the brunt of pathology 
During the course of PD, the neuropathological process mostly affects the PPN cholinergic 
neurons, whereas the GABAergic and glutamatergic populations are relatively spared of the 
disease [89, 108, 122]. We wanted to test whether this selective vulnerability pattern found 
in human postmortem PD brains also translates into our PFF murine model. Hence, we 
stained coronal sections containing the complete rostro-caudal extent of the PPN against p-
aSYN for aggregates, ChAT to visualize cholinergic neurons and MAP2 to stain all neuronal 
populations. 
Our analysis revealed that although cholinergic neurons form the smallest subpopulation of 
the PPN accounting only for approximately 25% of all neurons [181, 327], they displayed 
the vast majority of p-aSYN-positive aggregates in the PPN region (89.0 ± 10.4% for 6 wpi; 
76.9 ± 8.1% for 12 wpi) (Fig. 4.4A-C). At 6 wpi, approximately one-third of cholinergic 
neurons exhibited an aggregate (35.4 ± 8.4%), whereas at 12 wpi, the half of the cholinergic 




Figure 4.4 | The vast majority of the p-aSYN-positive aggregates co-localized with the cholinergic 
marker ChAT. 
A. Representative image of the PPN region 6 wpi stained for p-aSYN (white), ChAT (red) and DAPI (blue). 
Scale bar, 100 μm. 
B. High magnification confocal images of aggregate-containing cholinergic cells. Scale bar, 25 μm. 
C. The vast majority of p-aSYN aggregates was found in cholinergic PPN neurons (89.0 ± 10.4% at 6 wpi; 
76.9 ± 8.1% at 12 wpi; P < 0.001 for 6 wpi cholinergic versus non-cholinergic; P < 0.001 for 12 wpi 
cholinergic versus non-cholinergic; n = 4 at 6 wpi, n = 5 at 12 wpi; one-way ANOVA followed by Tukey’s 
multiple comparisons test). 
D. Quantification of the ratio of aggregate containing cholinergic PPN neurons on the injected (left) side 
(aggregate containing cholinergic neurons / all cholinergic neurons) reveals that around half of the PPN 
cholinergic neurons contain aSYN aggregates at 12 wpi (35.35 ± 8.44 at 6 wpi; 50.91 ± 2.8% at 12 wpi; P 
= 0,0057; n = 4 at 6 wpi; n = 5 at 12 wpi; unpaired t-test). 
 
 
4.1.5 Reactive microgliosis is induced at the injection site 
Profound reactive microgliosis is a common histopathological finding in brain regions 
affected by the PD disease process [84, 194]. Moreover, a growing body of evidence from 
epidemiological-, genome-wide association-, brain imaging-, postmortem histological-, and 
animal studies indicates that microglial activation is closely coupled to the neurodegenerative 
process [44, 90, 91, 93, 110, 127, 233, 295]. Therefore, we sought to investigate whether 
Lewy-like PPN pathology was accompanied by reactive microgliosis in our model.  
Our analysis revealed that the injection of both aSYN PFF’s and monomeric aSYN induced 
a similar degree of microglial activation at the injection site (Fig. 4.5A,B). Remarkably, there 
was also no difference in IbA1-positive pixel count in the contralateral (non-injected) PPN 
between PFF and monomeric aSYN injected animals, despite the fact that contralateral PPN 
neurons of PFF injected mice harbored p-aSYN-positive aggregates (Fig. 4.5B). This is an 
intriguing finding as it implicates that intraneuronal aggregation of aSYN per se does not 




Figure 4.5 | Injection of different aSYN species leads to reactive microgliosis in the PPN region. 
A. Graph showing percentage of IbA-1 positive pixels in PPN region. The amount of IbA-1 positive pixels 
was significantly higher on the injected side compared to the non-injected side for aSYN PFF injected 
animals but also for aSYN monomer injected mice (P = 0.0260 for 12 wpi mono contra versus 12 wpi 
mono ipsi; P = 0.0003 for 6 wpi PFF contra versus 6 wpi PFF ipsi; P = 0.0095 for 12 wpi PFF contra 
versus 12 wpi PFF ipsi; n = 5 for 12 wpi mono and 12 wpi PFF; n = 4 for 6 wpi PFF; one-way ANOVA 
followed by Tukey’s multiple comparisons test). Whisker box plots show median, lower and upper 
quartiles, and whiskers represent minimum and maximum of the data. 
B. High magnification images depicting different degrees of microglial (IbA1) activation. Scale bar, 25 μm. 
4.1.6 Significant decrease of ChAT-positive neuronal cell count 
The cascade of neuropathological events in human PD and animal models of PD lead to 
neuronal dysfunction and ultimately culminate in neuronal cell death. In postmortem PD 
brains, approximately 50% of large cholinergic neurons degenerate, whereas the GABAergic 
and glutamatergic neurons are relatively spared of the disease [89, 108, 122]. As we mainly 
observed pathological aSYN aggregation in the cholinergic PPN neurons, we sought to 
stereologically quantify cholinergic (ChAT- and NeuN-positive) and non-cholinergic, that is, 
GABAergic and glutamatergic (ChAT-negative but NeuN-positive) PPN neurons separately.  
We observed a significant decrease of ChAT-positive neurons of the ipsilateral (injected) 
PPN 12 wpi in PFF injected animals (617.4 ± 70.49 cells in PFF injected animals 12 wpi vs 
877 ± 94.89 cells in monomeric aSYN injected animals at 12 wpi; P = 0.0071) (Fig. 4.6A,C). 
The number of the contralateral (non-injected) cholinergic PPN neurons showed a 
decreasing tendency 6 and 12 wpi compared to monomeric aSYN injected animals, although 
this difference was not of statistical significance (717.8 ± 134.3 cells 6 wpi; 756.8 ± 80.85 
cells 12 wpi in PFF injected animals vs 848.8 ± 125.6 cells 12 wpi in monomeric aSYN 
injected animals). The number of non-cholinergic PPN neurons did not show any alterations 
6 and 12 wpi (5664 ± 590 cells 6 wpi ipsilaterally, 5435 ± 937 cells 6 wpi contralaterally, 5426 
± 448.6 cells 12 wpi ipsilaterally, 5203 ± 529 cells 12 wpi contralaterally in PFF injected 
animals vs 5143 ± 445.1 cells 12 wpi ipsilaterally, and 5331 ± 702.6 cells 12 wpi contralaterally 




Figure 4.6 | PFF injection into the PPN region leads to a significant decrease of ChAT-positive 
neurons. 
A. aSYN PFF treatment induces loss of ChAT pos. PPN neurons at 12 wpi (877 ± 94.89 vs 617.4 ± 70.49 
cells; P = 0.0071 for 12 wpi mono ipsi versus 12 wpi PFF ipsi; for all other comparisons P > 0.05; n = 5 
for 12 wpi mono and 12 wpi PFF; n = 4 for 6 wpi PFF; one-way ANOVA followed by Dunnett’s multiple 
comparisons test).  
B. The number of non-cholinergic neurons was not changed in any group or time point (P > 0.05 for all 
comparisons; n = 5 for 12 wpi mono and 12 wpi PFF; n = 4 for 6 wpi PFF; one-way ANOVA followed by 
Dunnett’s multiple comparisons test). 
C. Representative images of the PPN region for each group and time point. Scale bar, 500 μm. 
 
4.1.7 Initial spreading of pathology occurs as soon as 1 wpi 
Previous studies have demonstrated that PFF’s initiate a cascade of pathological events 
mediated by seeding recruitment of primarily soluble endogenous aSYN [178, 320, 321]. In 
vivo, the induced pathology is not restricted to the close vicinity of the injection site but 
spreads over considerable distances to regions far beyond the initial inoculation in a 
stereotypical temporal and topological manner [179, 189, 190, 242, 243]. Mounting evidence 
suggests that this propagation of pathology occurs through synaptic connections and 
depends on the wiring architecture (connectome4) of the brain region in which the initial 
seeding took place. To investigate the neuroanatomical distribution of pathology in our 
murine PFF model, we sought to generate a highly comprehensive and quantitative map of 
the brain-wide Lewy-like pathology. Therefore, we stained p-aSYN in coronal brain sections 
with an interslice distance of 240 μm covering the complete rostro-caudal extent of the brain 
from the OB to the spinal cord. We thereafter generated a grading system distinguishing 
somal and axonal/neuritic pathology (see chapter 3.4.8 and Fig. 3.3) and systematically 
graded the observed p-aSYN pathology in distinct brain regions. 
One-week post-injection, apart from the PPN, 16 regions stained positive for somal and/or 
neuritic Lewy-like pathology (Fig. 4.7A). Fifteen regions were located in the ipsilateral (left) 
hemisphere, whereas one region (tuberal nucleus) was affected bilaterally (Fig. 4.8). The 
observed pathology was most severe at the inoculation site, followed by the retrorubral field, 
                                                 
4 Comprehensive map of the synaptic connections formed between neurons of the nervous system. 
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medial and lateral parts of the central amygdala, and parabrachial nucleus. Next, we wanted 
to examine whether and how strong neuritic and somal pathology were associated, i.e. how 
well the scores correlated with each other. Therefore, we plotted the neuritic and somal 
pathology scores and performed a linear regression analysis. We observed a strong 
correlation between the somal and neuritic pathology scores (r2 = 0.88) (Fig. 4.7D). Thirteen 
out of the sixteen distant brain regions exhibited both neuritic and somal pathology, whereas 
only three regions displayed either somal or neuritic scores.  
 
Figure 4.7 | Brain-wide propagation of the α-synucleinopathy 1 wpi 
A. Whole-brain quantification of p-aSYN neurite (N) and soma (S) pathology at 1 wpi reveals aSYN 
pathology in 17 brain regions (n = 3). 
B. Caudo-rostral distribution of brain regions relative to the injection site (left PPN, 0) showing neuritic 
pathology 1 wpi.  
C. Caudo-rostral distribution of brain regions relative to the injection site (left PPN, 0) showing somal 
pathology 1 wpi. 
D. p-aSYN soma pathology correlated strongly with p-aSYN neurite pathology 1 wpi (r2 = 0.88, n=3). 
Abbreviations: ACB, nucleus accumbens; BSTov, bed nuclei of the stria terminalis, anterior division, oval nucleus; CEAl, 
central amygdala, lateral part; CEAm, central amygdala, medial part; CP, caudoputamen; GPi, globus pallidus internus; IC, 
inferior colliculus; LHA, lateral hypothalamic area; MRN, midbrain reticular nucleus; NLL, nucleus of the lateral lemniscus; 
PAG, periaqueductal gray; PB, parabrachial nucleus; PPN, pedunculopontine nucleus; PRNr, pontine reticular nucleus, 






To exclude the possibility of simple diffusion of the injected PFF’s, we plotted the degree of 
p-aSYN pathology observed in individual brain regions with their caudo-rostral distances 
relative to the injection site (left PPN, Bregma ‒4.6, 0 mark on the graph) (Fig. 4.7B,C). We 
observed that the distribution of pathology over the rostro-caudal extent of the brain did not 
show any regularity. Brain regions far away from the injection site showed similar severity of 
p-aSYN pathology as did brain structures adjacent to the PPN. The distribution of pathology 
did not show characteristics of diffusion, i.e. the degree of induced pathology did not 
decrease with longer distances to the injection site (Fig. 4.7B,C). Remarkably, our analysis 
revealed that the initial propagation of Lewy-like pathology occurred in a clear caudo-rostral 
direction. While out of the sixteen regions, fifteen were rostral to the PPN, only one region 
(parabrachial nucleus) localized a bit caudally.  
To clearly demonstrate the distribution and burden of α-synucleinopathy induced by focal 
PFF injection into the left PPN, we generated comprehensive heatmaps of both the brain-
wide somal (Fig. 4.8A) and neuritic p-aSYN pathology (Fig. 4.8B). No p-aSYN pathology 
was seen in monomeric aSYN injected animals at any time-point (data not shown). 
 
Figure 4.8 | Brain-wide distribution of Lewy-like pathology 1 wpi 
A. Heatmaps depicting degree of somal p-aSYN pathology 1 week after PFF injection into the left PPN (red 
circle). For more information on the grading system see 2.3.8. n = 3 
B. Heatmaps depicting degree of axonal/neuritic p-aSYN pathology 1 week after PFF injection into the left 
PPN (red circle). For more information on the grading system see 2.3.8. n = 3 
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4.1.8 Brain-wide p-aSYN pathology progresses in severity and distribution 
To investigate the time-dependency of the pathological changes induced by focal PFF 
injection into the left PPN, we stained and analyzed coronal sections with an interslice 
distance of 240 μm of the whole murine brain at the 6 wpi time-point. The staining and 
grading protocols were identical to the 1-week time-point (see 4.1.7). 
Systematic p-aSYN pathology mapping revealed 278 brain regions harboring somal p-aSYN 
pathology, and 286 regions exhibiting neuritic/axonal p-aSYN signal at 6 wpi (Fig. 4.9). The 
affected brain regions were distributed throughout the whole brain spanning from the OBs 
and prefrontal cortices to the spinal cord, the farthest region being as far as 7.19 mm from 
the inoculation site (medial and dorsal parts of the anterior olfactory nucleus, inoculation 
site: left PPN region, Bregma -4.6 mm). In spite of the unilateral injection of aSYN fibrils, 
the p-aSYN pathology appeared in both hemispheres, but was more abundant in the 
ipsilateral (left) hemisphere. The observed pathology was most severe at the inoculation site 
within the left PPN, followed by the lateral and medial parts of the central amygdala, 
laterodorsal tegmental nucleus, sublaterodorsal tegmental nucleus, anterolateral area and 
rhomboid nucleus in the anterior division of the bed nuclei of the stria terminalis, 
periaqueductal gray, midbrain reticular nucleus, and lateral hypothalamic area. Distant 
aggregates stained also positive for p62 indicating that these inclusions, such as the ones at 




Figure 4.9 | Brain-wide distribution of Lewy-like pathology 6 wpi 
A. Heatmaps depicting degree of somal p-aSYN pathology 6 weeks after PFF injection into the left PPN 
(red circle). For more information on the grading system see 2.3.8. n = 4 
B. Heatmaps depicting degree of axonal/neuritic p-aSYN pathology 6 weeks after PFF injection into the left 
PPN (red circle). For more information on the grading system see 2.3.8. n = 4 
Next, we wanted to test whether the strong correlation between the neuritic and somal 
pathology observed at the one-week time-point is still apparent at the six-week time-point. 
We therefore plotted the somal and neuritic p-aSYN pathology scores of the respective brain 
areas and performed a linear regression analysis (Fig. 4.10C). A strong correlation of the two 
pathology scores was observed at 6 wpi (r2 = 0.9082, n = 4).  
Next, we wanted to analyze the time-dependency of the brain-wide progression of 
pathological changes following unilateral aSYN fibril injection. Therefore, we compared both 
the whole brain distribution and the severity of the observed pathology at the respective 
brain regions 1 and 6 wpi.  
Significantly more regions were affected by p-aSYN pathology at 6 wpi compared to 1 wpi 
(for somal pathology: 278 regions 6 wpi vs 15 regions 1 wpi; for neuritic pathology: 286 
regions at 6 wpi vs 15 regions 1 wpi). At the six-week time-point, pathology also spread to 
caudal regions relative to the injection site, such as the gigantocellular nucleus, or the 
intermediate reticular nucleus (Fig. 4.9). Remarkably, all regions showing severe pathology 




All 17 brain regions affected at 1 wpi showed considerable p-aSYN pathology also at 6 wpi. 
Comparison analysis revealed that all regions except three displayed a significantly more 
severe pathology 6 wpi than they did 1 wpi (P < 0.05; n = 4 for 6 wpi, n = 3 for 1 wpi; 
multiple t-tests adjusted with Holm-Sidak method).  The only exceptions were the internal 
segment of the globus pallidus (GPi), tuberal nucleus of the hypothalamus (TU), and the 
parabrachial nucleus (PB), which showed similar degree of pathology at both time-points. 
 
 
Figure 4.10 | Brain-wide p-aSYN pathology progresses over time 
A. p-aSYN neurite scores 1 and 6 wpi of the 17 regions displaying p-aSYN pathology 1 wpi. Neurite 
pathology significantly increased 6 wpi in all depicted regions, except for those highlighted in grey (P = 
0.0001, <0.0001, <0.0001, <0.0001, <0.0001, <0.0001, 0.0018, <0.0001, 0.0074, <0.0001, <0.0001, 
<0.0001, <0.0001, 0.0021, <0.0001 for CP, ACB, CEAl, CEAm, GPi, LHA, IC, VTA, RR, MRN, PAG, 
PPN, NLL, PB, and PRNr, respectively; n = 3 for 1 wpi; n = 4 for 6 wpi; multiple t-tests adjusted with 
Holm-Sidak method). 
B. p-aSYN soma scores 1 and 6 wpi of the 17 regions displaying p-aSYN pathology 1 wpi. Neurite pathology 
significantly increased 6 wpi in all depicted regions, except for those highlighted in grey (P = <0.0001, 
<0.0001, <0.0001, <0.0001, <0.0001, <0.0001, 0.0010, <0.0001, 0.0044, <0.0001, <0.0001, <0.0001, 
<0.0001, <0.0001 for CP, ACB, CEAl, CEAm, BSTov, LHA, IC, VTA, RR, MRN, PAG, PPN, NLL, 
and PRNr, respectively; n = 3 for 1 wpi; n = 4 for 6 wpi; multiple t-tests adjusted with Holm-Sidak 
method). 
C. p-aSYN neurite and soma pathology showed strong correlation 6 wpi (n = 4; r2 = 0.9082). 
D. Representative high magnification confocal images of the aggregates found in distant brain regions. 
Aggregates stained positive for both p-aSYN and p62. Scale bar, 25 μm. 
Abbreviations: ACB, nucleus accumbens; BSTov, bed nuclei of the stria terminalis, anterior division, oval nucleus; CEAl, 
central amygdala, lateral part; CEAm, central amygdala, medial part; CP, caudoputamen; GPi, globus pallidus internus; IC, 
inferior colliculus; LHA, lateral hypothalamic area; MRN, midbrain reticular nucleus; NLL, nucleus of the lateral lemniscus; 
PAG, periaqueductal gray; PB, parabrachial nucleus; PPN, pedunculopontine nucleus; PRNr, pontine reticular nucleus, 




4.3 The rAAV model of Parkinson’s disease 
4.3.1 Experimental design 
The discovery that missense mutations and duplications/triplications of the aSYN gene 
(SNCA) cause familial forms of PD has prompted the development of animal models based 
on the overexpression of aSYN [145, 229, 285]. Two different approaches could be 
distinguished: 1) development of transgenic mouse lines overexpressing human/murine 
wild-type or mutated aSYN under several distinct promotors [79, 171, 184, 186, 197, 203, 
246]; 2) targeted, viral vector mediated overexpression of aSYN in the nigrostriatal system 
[49, 72, 131, 142, 147, 148, 344]. Whereas former models exhibit aSYN accumulation and 
Lewy-like pathology in the central nervous system, but are mostly devoid of nigral and LC 
neurodegeneration [322], latter approach showed repeatedly high efficiency in replicating 
both the Lewy-like pathology and the cellular death of the dopaminergic SNc. However, up 
until now, no data exists on the effects of targeted aSYN overexpression in the noradrenergic 
LC. 
To study the brain-wide effects of aSYN accumulation selectively induced in the 
noradrenergic LC region of wild-type mice, we chose to overexpress human mutated A53T-
aSYN with a viral vector mediated approach. A chimeric rAAV vector of serotype 1/2 was 
used combining the advantages of rAAV serotype 1 (excellent brain penetration), and rAAV 
serotype 2 (high neuronal tropism). The chosen promotor was the CMV promotor (Fig. 
4.11B), which belongs to the strongest known promotors to mediate transient and stable 
exogenous gene transcription. However, a considerable draw-back of this promotor is its 
unspecificity: it induces protein expression in neuronal cells as well as adjacent glial and 
endothelial cells. 
To investigate the time-dependency of the brain-wide pathology progression, mice were 
consecutively sacrificed 1, 3, 6, and 9 wpi and their brains were processed for thorough 







4.3.2 Successful overexpression of human A53T-aSYN in the LC 
Targeted overexpression of aSYN in the murine LC region is an until now unprecedented 
approach and the viral vectors used in this study have only been applied to the dopaminergic 
SNc region [131, 147, 148]. Therefore, we first sought to verify successful transduction5 of 
the noradrenergic LC after loco-regional viral vector delivery. Therefore, we double stained 
coronal sections containing the whole rostro-caudal extent of the LC against tyrosine 
hydroxylase (TH), a common marker of noradrenergic neurons, and human aSYN (Syn211) 
or Luciferase (control). 
Our analysis revealed successful transduction of the LC region by both the rAAV-A53T-
aSYN vector, indicated by human aSYN overexpression (Fig. 4.11C), and the rAAV-Luc 
vector, indicated by Luciferase overexpression (data not shown). Due to the unspecificity of 
the CMV promotor, overexpression was not restricted to the TH-positive (noradrenergic) 
LC cells but was also evident in adjacent TH-negative brain regions, such as the parabrachial 
nucleus, Barrington’s nucleus, mesencephalic trigeminal and vestibular nuclei (Fig. 11C). 
Robust human aSYN labeling was detectable in the cell bodies as well as axons and dendrites 
of the transduced cells indicating strong protein overexpression. 
 
Figure 4.11 | Local viral vector driven 
overexpression of human A53T-aSYN in the LC 
region 
A. Schematic depicting experimental design. rAAV-
A53T-aSYN or –Luc vectors were iúnilaterally 
injected into the right LC region of wild-type 
mice. Animals were then consecutively sacrificed 
1, 3, 6, and 9 wpi and their brains were processed 
for thorough immunohistochemical analysis. 
B. Schematic of the viral vector map. ITR, inverted 
terminal repeat; CMV/CBA, chicken β-actin 
promotor hybridized with a CMV immediate 
early enhancer sequence; WPRE, woodchuck 
hepatitis virus posttranscriptional regulatory 
element; BGH-pA, bovine growth hormone 
polyadenylation sequence. Viral vector design 
published in [116]. 
C. Representative image of human A53T-aSYN 
overexpression in the noradrenergic LC region of 
mice at 1 wpi. Tyrosine hydroxylase (TH), red; 
human aSYN (haSYN), green. Scale bar, 100 μm. 
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4.3.3 Brain-wide transport of human A53T-aSYN as soon as 1 wpi 
A few previous studies utilizing viral vector mediated overexpression of aSYN to model PD 
in animals have described that regionally restricted expression of human aSYN leads to 
considerable neuron-to-neuron propagation of the protein in the central nervous system 
[115, 255, 311–313]. In vivo studies implicate that this spreading of human aSYN in the 
murine brain is an active process requiring intact and relatively healthy neurons and involves 
non-fibrillar forms of aSYN [115, 312]. To investigate whether restricted overexpression of 
A53T-aSYN in the LC region in our PD model led to brain-wide propagation of human 
aSYN, we stained eight coronal sections (Bregma: +4.28, +2.86, +1.18, +0.38, −0.58, −3.16, 
−6.96, and −7.56) covering the complete mouse brain against human aSYN (Syn211) or 
Luciferase (control). We thereafter generated a grading system (see chapter 3.4.9) and 
systematically graded the observed axonal and somal human aSYN burden in distinct brain 
regions. 
 
Figure 4.12 | Brain-wide distribution of human aSYN at the respective time-points. 
Heatmaps depicting degree of axonal human aSYN-signal 1, 3, 6, and 9 wpi. For more information on the 





One-week post-injection, robust axonal human aSYN labeling was already observable in 
several brain regions (Fig. 4.12). Despite the unilateral injection of rAAVs, even at this early 
time-point, the axonal signal appeared bilaterally, however, the ipsilateral (right) hemisphere 
was affected more severely. The affected brain regions were distributed throughout the 
whole brain from the OBs (main olfactory bulb, granular layer) to the caudal medulla 
(gigantocellular and intermediate reticular nuclei) with the farthest positive region being as 
far as 8.83 mm away from the injection site (right LC, Bregma −5.4 mm). The most abundant 
human aSYN signal was detected in the lateral and medial septal nuclei, bed nuclei of the 
stria terminalis, lateral hypothalamic area, and the midbrain reticular nucleus. Remarkably, 
no aSYN signal was detected in cell bodies distant from the injection site. 
At later time-points (3, 6, and 9 wpi), axonal human aSYN-signal was more abundantly 
distributed throughout the whole brain and more regions were affected bilaterally compared 
to 1 wpi. All regions displaying human aSYN-signal at 1 wpi also exhibited axonal pathology 
at later time-points. The most severely affected regions were the main olfactory bulb, lateral 
septal nucleus, diagonal band nucleus, bed nuclei of the stria terminalis, central amygdalar 
nucleus, periaqueductal gray, midbrain reticular nucleus, SNc, and the ventral tegmental area. 
Further statistical testing of 21 selected brain structures revealed that the vast majority of 









Figure 4.13 | Human aSYN score is significantly increased over time in a subset of brain regions 
ipsilateral from the injection site. 
Graph depicting human aSYN score in preselected brain regions 1, 3, 6, and 9 wpi. gr: P <0.0001 for 1 vs 3 
wpi and 1 vs 6 wpi, 0.0008 for 1 vs 9 wpi, 0.0282 for 6 vs 9 wpi; AON: P = 0.00483 for 1 vs 3 wpi; ipl: P = 
<0.0001 for 1 vs 3 wpi and 1 vs 6 wpi, 0.0002 for 1 vs 9 wpi; opl: P = 0.0013 for 1 vs 3 wpi, 0.0030 for 1 vs 6 
wpi, 0.0099 for 1 vs 9 wpi; TTd: P = 0.0008 for 1 vs 3 wpi, P < 0.0001 for 1 vs 6 wpi, and 0.0099 for 1 vs 9 
wpi; LS: P = 0.0002 for 1 vs 3 wpi, and < 0.0001 for 1 vs 6 and 1 vs 9 wpi; NDB: P = 0.0002 for 1 vs 3 wpi, 
and <0.0001 for 1 vs 3 and 1 vs 6 wpi; CLA: P = < 0.0001 for 1 vs 3, 1 vs 6, and 1 vs 9 wpi, and 0.0282 for 3 
vs 6 wpi; Epd: P = 0.0030 for 1 vs 3 wpi, <0.0001 for 1 vs 6 wpi, 0.0002 for 1 vs 9 wpi, 0.0030 for 3 vs 6 wpi, 
and 0.0282 for 6 vs 9 wpi; MS: P = 0.0008 for 1 vs 6 wpi; BST: P = 0.0010 for 1 vs 3 wpi, and <0.0001 for 1 
vs 6, and 1 vs 9 wpi; LHA: P = 0.0036 for 1 vs 3 wpi, and <0.0001 for 1 vs 6, and 1 vs 9 wpi; CEA: P = 0.0009 
for 1 vs 3 wpi, <0.0001 for 1 vs 6, 1 vs 9, and 3 vs 9 wpi, and 0.0016 for 3 vs 6 wpi; SNc: P = 0.0008 for 1 vs 
6 wpi, and 0.0030 for 1 vs 9 wpi; VTA: P < 0.0001 for 1 vs 6, and 1 vs 9 wpi; SCm: P = 0.0008 for 1 vs 3 wpi, 
<0.0001 for 1 vs 6, and 1 vs 9 wpi, and 0.0099 for 3 vs 9 wpi; GRN: P = 0.0157 for 1 vs 6 wpi; DMV: P < 
0.0001 for 1 vs 6, and 1 vs 9 wpi. n = 6 per time-point. Two-way ANOVA with post-hoc Tukey’s multiple 
comparisons tests.  
Abbreviations: ACB, nucleus accumbens; AON, anterior olfactory nucleus; BST, bed nuclei of the stria terminalis; CEA, 
central amygdalar nucleus; CLA, claustrum; CP, caudoputamen; DMV, dorsal motor nucleus of the vagal nerve; Epd, 
endopiriform nucleus, dorsal part; GRN, gigantocellular nucleus; LHA, lateral hypothalamic area; LS, lateral septal nucleus; 
MOBgr, main olfactory bulb, granule layer; MOBipl, main olfactory bulb, inner plexiform layer; MOBopl, main olfactory 
bulb, outer plexiform layer; MS, medial septal nucleus; NDB, diagonal band nucleus; SCm, superior colliculus, motor 
related; SNc, substantia nigra, pars compacta; SNr, substantia nigra, pars reticulata; TTd, taenia tecta, dorsal part; VTA, 
ventral tegmental area. 
 
Human aSYN signal was exclusively found in axons and synaptic boutons (Fig. 4.14A-D, 
high magnification images), and no human aSYN signal was detected in cell bodies apart 
from the injection site at any time-point. No Luciferase signal was found in in distant brain 





Figure 4.14 | Widespread axonal transport of human A53T-aSYN to distant brain regions. 
A-D.  Representative images of analyzed brain sections stained against human aSYN (Syn211) 6 wpi (A. 
Bregma +0.50 mm; B. Bregma −0.94 mm; C. Bregma −3.16 mm; D. −7.56 mm). Scale bar, 1 mm in 
overview images, 25 μm in high magnification images. Figure was published in [116]. 
Abbreviations: aco, anterior commissure; AP, area postrema; APN, anterior pretectal nucleus; BST, bed nuclei of stria 
terminalis; CEA, central amygdalar nucleus; CP, caudoputamen; CTX, cortex; CU, cuneate nucleus; DG, dentate gyrus; DMX, 
dorsal motor nucleus of the vagus nerve; ECU, external cuneate nucleus; fi, fimbria hippocampi; GP, globus pallidus; HPF, 
hippocampal formation; HY, hypothalamus; icp, inferior cerebellar peduncle; int, internal capsule; IO, inferior olivary 
complex; IRN, intermediate reticular nucleus; L, left (contralateral); LHA, lateral hypothalamic area; LRN, lateral reticular 
nucleus; LS, lateral septal nucleus; MDRNd, medullary reticular nucleus, dorsal part; MDRNv, medullary reticular nucleus, 
ventral part; mlf, medial longitudinal fascicle; MRN, midbrain reticular nucleus; MS, medial septal nucleus; NTS, nucleus of 
the solitary tract; OT, olfactory tubercle; PAG, periaqueductal gray; py, pyramid; R, right (ipsilateral); RA, raphe nuclei; sAMY, 
striatum-like amygdalar nuclei; SC, superior colliculus; SI, substantia innominata; SNc, substantia nigra pars compacta; SNr, 
substantia nigra pars reticulata; sptV, spinal tract of the trigeminal nerve; SPV, spinal nucleus of the trigeminal; TH, thalamus; 




4.3.4 Pathological forms of aSYN are not detectable in distant brain regions 
Several previous studies indicate that the progression of Lewy-pathology in PD and PD 
animal models relies on the intercellular transport of toxic, aggregation-prone aSYN species 
[99]. According to this hypothesis, pathological forms of aSYN are formed within a subset 
of neuronal cells (donors), and then transported to synaptically connected neurons 
(recipients) where they act as seeds triggering the aggregation of endogenous, primarily 
soluble aSYN.  
In our murine model of prodromal PD, we induced the overexpression of human aSYN in 
the noradrenergic LC region. Pathological, p-aSYN-, p62-, and Ubi-1-positive forms of 
aggregated aSYN were observable as soon as 1 wpi at the inoculation site [116]. We 
hypothesized, according to the above theory, that these aggregate harboring cells could act 
as donors of pathological aSYN and promote the transmission of aSYN aggregates to distant 
brain regions. As the aggregate formation in the recipient neurons involves endogenous 
murine aSYN, the antibody against human aSYN (Syn211) used in the previous analysis 
(chapter 4.3.3) would only detect the artificially overexpressed aSYN and not the induced 
pathology in distant brain regions. Therefore, to test whether pathological aSYN species are 
observable in distant neurons, we stained coronal sections with an interslice distance of 
240 μm of the whole murine brain against common markers of pathological aSYN, namely 
p-aSYN, p62, and Ubi-1. 
In contrast to the above proposed hypothesis, our whole-brain analysis revealed that brain 
regions distant from the injection site were devoid of pathological forms of aSYN even at 
the longest, nine-week time-point (data not shown). None of the regions displaying high 
axonal human aSYN burden (e.g. bed nuclei of the stria terminalis, central amygdalar nucleus, 
periaqueductal gray) did exhibit p-aSYN, p62, or Ubi-1 positive aSYN species. Signal was 









4.3.5 No degeneration of the dopaminergic SNc was detectable 9 wpi 
Previous studies have demonstrated that loco-regional viral vector mediated overexpression 
of human aSYN leads to propagation of aSYN through neuronal connections and 
progressive neurodegeneration of secondary brain regions [255, 311]. We wanted to 
investigate whether this also translates into our mouse model. Therefore, we stereologically 
quantified dopaminergic, TH-positive neurons of the SNc 9 wpi in A53T-aSYN and 
Luciferase overexpressing animals. 
Despite the unilateral injection of rAAV vectors, transport of human aSYN was observed 
bilaterally, although the ipsilateral (right) SNc displayed more abundant human aSYN-signal. 
Human aSYN-positive axons were observable as soon as 1 wpi in the SNc region, and at 9 
wpi, the region was densely covered (Fig. 4.15A). However, no human aSYN-signal was 
detectable in TH-positive dopaminergic SNc somata at any time-point. 
Unbiased stereological quantification revealed no significant difference in the number of TH-
positive neurons of A53T-aSYN overexpressing animals compared to Luciferase 
overexpressing mice (Fig. 4.15B). Difference was neither present ipsi-, nor contralaterally to 
the injection site. 
 
Figure 4.15 | No degeneration of dopaminergic SNc neurons 9 wpi. Figure published in [116]. 
A. Representative overview image of the right SNc region of wild-type mice overexpressing human A53T-
aSYN in the LC region. Scale bar, 250 μm 
B. Quantification of TH-positive SNc neurons revealed to significant difference between A53T-aSYN (red 
bars) and Luciferase (black bars) overexpressing animals 9 wpi. Values are presented as mean ± SEM, 









The purpose of the herein presented study was twofold: (1) we wanted to establish a new 
PFF-induced mouse model of PD at the level of the mesopontine PPN and investigate 
whether the selective vulnerability pattern of this nucleus in human PD also translates into a 
PFF mouse model; (2) we wanted to compare the aSYN propagation pattern in two distinct 
aSYN-based animal models. 
In the first part of the study we showed that loco-regional PFF injection led to intraneuronal 
aggregate formation in the PPN. Inclusion bodies were immunoreactive to p-aSYN and p62, 
and were proteinase resistant thereby recapitulating several key features of human LBs. 
Remarkably, despite representing only around 25% of PPN neurons, cholinergic cells 
harbored the brunt of p-aSYN pathology, and also displayed significant cell loss 12 wpi. 
Interestingly, reactive microgliosis was observed both in PFF and monomeric aSYN 
(control) injected animals, although no other pathology was observed in control animals. 
Additionally, injection of PFF’s led to widespread transneuronal propagation of p-aSYN to 
brain regions far beyond the injection site. Pathology was found in perikarya (somal 
pathology) reminiscent of LBs as well as in axons reminiscent of human LNs. 
In the second part of the study we showed that targeted, viral vector mediated overexpression 
of human mutated A53T-aSYN in the noradrenergic LC led to widespread axonal transport 
of human aSYN to distant brain regions. Interestingly, signal was exclusively found axonally 
and no cell bodies were positive outside the primarily transduced LC region. No pathological 
forms of aSYN were detected in distant brain regions. Additionally, unbiased stereological 
quantification of the dopaminergic SNc revealed no significant cell loss at the relatively short 
time-frame of 9 weeks. 
5.1 The fibril model of Parkinson’s disease 
5.1.1 PFF’s lead to Lewy body-like aggregate formation 
One of the major neuropathological hallmarks of PD are intraneuronal aSYN-containing 
proteinaceous inclusion bodies called LBs or LNs, based on the predominant location in 
perikarya or axons [30]. Postmortem studies of PD patients revealed that approximately 90% 
of aSYN found in LBs is phosphorylated at serine 129 (S129-phosphorylation), whereas only 
4% of soluble monomeric aSYN is phosphorylated at this residue indicating that this 
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posttranslational modification of aSYN occurs during the pathogenic process of PD and 
might increase the aggregation propensity of the protein [5, 85, 114, 230, 262, 275]. 
Therefore, the detection of S129-phosphorylated aSYN serves as a common aggregation 
marker both in human neuropathological studies as well as in animal models of PD [16, 177, 
179, 242, 259]. In our model, a single inoculation of pathological PFF into the PPN region 
of mice induced progressive accumulation of aSYN inclusions at the injection site as 
evidenced by p-aSYN staining. As the exogenously injected PFF’s are unphosphorylated, 
detection of S129-phosphorylation in our model reflects an intracellular modification. Based 
on their location and shape, two types of aggregates could be distinguished: (1) large somal, 
located in the perinuclear region of the neuronal cell bodies; and (2) small, thread-like 
aggregates most likely located in axonal processes. The aggregates were highly reminiscent 
of human LBs and LNs found in postmortem PD brain tissues. 
Several studies have raised doubts whether the mere detection of p-aSYN truly proves the 
presence of high molecular weight aSYN aggregates [116, 275, 303]. Therefore, we 
investigated additional aggregation markers used in postmortem neuropathological studies: 
p62-positivity and PK resistance.  
The cell possesses several distinct pathways to get rid of toxic, misfolded, or unnecessary 
proteins. The two major pathways are: (1) ubiquitin-proteasome system, which is used to 
degrade small or intermediate forms of pathological aSYN, such as oligomers; and (2) the 
autophagy-lysosomal pathway, a catabolic cellular process in which higher molecular weight 
aSYN forms are removed [318]. p62, also called sequestosome-1 (SQSTM1) is a stress-
inducible protein which acts as an autophagy receptor: it binds to cargos such as 
ubiquitinated aggregates and directs them toward selective autophagy [146]. In 
neurodegenerative proteinopathies, including PD, the accumulating aggregates display p62-
positivity, which is therefore commonly used to screen for aggregated forms of various 
proteins [157, 158]. In our model, almost all the p-aSYN-positive aggregates stained also 
positive for p62 indicative of an overloaded or dysfunctional autophagy-lysosomal pathway. 
p62-positivity was observed in both large perinuclear as well as thread-like axonal inclusions. 
A common method to prove (or disprove) insolubility of protein aggregates is by digestion 
of the tissue with broad-spectrum proteases such as Proteinase K (PK), which was used in 
several postmortem neuropathological studies to demonstrate the insolubility of aSYN 
aggregates in PD brains [131, 203, 275]. Therefore, we performed PK digestion on our brain 
tissue samples and thereafter stained for p-aSYN in combination with p62. We could show 
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that the vast majority of the developing p-aSYN- and p62-positive aggregates at the injection 
site were truly insoluble protein inclusions. 
Taken together, PFF injection into the PPN region induced aSYN inclusion formation 
recapitulating several key features of human LBs and LNs, such as p-aSYN- and p62-
positivity and PK resistance. Our results prove that PFF’s possess prion-like properties in vivo 
by templating and seeding the misfolding of endogenous murine aSYN thereby triggering 
the aggregation of primarily native and soluble aSYN.  
5.1.2 Cholinergic PPN neurons are selectively vulnerable to PFF’s 
The PPN is a neurochemically heterogeneous structure composed of three distinct neuronal 
subtypes: cholinergic, GABAergic, and glutamatergic [327]. In neuropathological studies of 
PD brains, despite this inherent heterogeneity, the occurrence of LBs predominates in 
cholinergic neurons [108]. Additionally, cholinergic neurons seem to be more susceptible to 
the disease process than GABAergic neurons, as the loss of cholinergic neurons is reported 
to be up to 57%, whereas only around 18% of GABAergic neurons are lost during the disease 
process [117, 122, 137, 226, 249]. 
We found that the specific pattern of pathology distribution seen in human PD brains also 
translates into our PFF model. Although all neuronal subtypes were exposed to the same 
extracellular PFF concentration, the distribution of p-aSYN aggregates between the three 
neuronal subtypes did not follow the natural proportional composition of PPN: in spite of 
representing the smallest cell group of the PPN (up to 25% of neurons) [181], the vast 
majority of aggregates localized to cholinergic neurons (up to 89% 6 wpi, and 77% 12 wpi). 
Additionally, we detected selective and significant loss of ChAT-positive (cholinergic) 
neurons, whereas neuronal counts of non-cholinergic neurons did not show any alterations 
within the observational period of 12 weeks. The loss of ChAT-positive neuronal count can 
implicate loss of acetyl choline transferase (ChAT) expression, cholinergic neuronal cell 
death, or a mixture of both. 
The finding that cholinergic PPN neurons are particularly susceptible to PFF induced 
pathology is intriguing. Currently, due to the sparse knowledge and data on PPN neurons, 
we can only speculate the underlying cellular factors for this differential susceptibility. In the 
following paragraphs, we will give a brief list of factors which might contribute to the 
observed vulnerability of cholinergic, and partial resistance of non-cholinergic neurons to 
PFF induced pathology. 
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1. Expression of f ibri l  receptors 
The prerequisite for pathological aSYN seeding by exogenously inoculated PFF’s is their 
internalization into cellular compartments where soluble endogenous aSYN is present. A 
large body of evidence indicates that aSYN PFF’s are taken up by neurons via receptor 
mediated endocytosis [124, 169, 183]. Several cell-surface molecules have been found to bind 
aSYN PFF’s, including heparin sulfate proteoglycans, neurexin 1β, amyloid β precursor-like 
protein 1 (APLP1), or lymphocyte-activation gene 3 (LAG3) [124, 126, 183]. In vitro 
experiments by Mao and colleagues implicated a dose-dependent effect of LAG3 receptors 
on the rate of PFF internalization, as LAG3 overexpression significantly enhanced PFF 
internalization, whereas LAG3 knockout cells exhibited only minimal PFF endocytosis [183]. 
Additionally, deletion of LAG3 significantly attenuated PFF-induced neuropathology in the 
CNS of LAG3 knockout mice, however, did not fully abolish intracerebral aggregate 
formation [183]. This suggests that LAG3 is a significant, but not exclusive mediator of PFF 
internalization. 
Data on the different expression level of LAG3 and potentially other receptors mediating 
PFF internalization by different neuronal subtypes are not existing. However, different level 
of fibril-receptor expression might significantly contribute to the vulnerability neurons. 
2. Endogenous aSYN-levels 
Multiplication of the SNCA (aSYN gene) leads to autosomal dominantly inherited PD. A 
clear relationship between the level of aSYN expression (copy number of the gene) and the 
age of onset, distribution of neuropathology, severity of disease, and pace of progression 
could be observed, implicating a dose-dependent effect of aSYN [42, 128]. PFF’s, similar to 
prion proteins, serve as templates and trigger the misfolding and aggregation of endogenous 
aSYN in vitro and in vivo (homologous seeding). The seeding capacity of PFF’s depends on 
the presence and concentration of their endogenous counterparts [138, 179, 190, 320].  
Although a comprehensive map of aSYN expression levels in distinct brain regions and 
neuronal subtypes is lacking, a few studies investigated key brain areas in the development 
of PD. The level of aSYN expression significantly differed between neuronal subtypes. 
Generally, GABAergic neurons and interneurons showed the least immunoreactivity to 
aSYN, whereas catecholaminergic neurons showed a rather robust labeling [22, 299, 300]. 
The level of aSYN expression in glutamatergic synapses varied considerably between 
different brain regions [300].  
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Studies specifically investigating aSYN expression levels in distinct PPN neuronal subtypes 
are lacking. However, it is tempting to speculate that the observed resilience to PFF induced 
pathology of GABAergic neurons in the PPN might partly be due to their low aSYN 
expression levels. 
3. aSYN phosphorylation capacity 
Around 4% of aSYN is phosphorylated at serine 129 physiologically, whereas over 90% of 
aSYN found in LBs is phosphorylated at this residue [85]. The exact pathophysiological 
relevance of this post-translational modification, however, is still controversial. 
In vitro studies showed that phosphorylation of monomeric aSYN increases its propensity to 
self-assemble into fibrils and aggregates [85, 262, 287]. Moreover, targeted injection of 
primarily phosphorylated PFF’s induced more severe aggregate formation and 
neurodegeneration in vivo than did non-phosphorylated or phosphorylation deficient PFF’s 
implicating that S129-phosphorylation enhances the aggregation propensity and 
neurotoxicity of the fibrils [138]. However, reports on unaltered toxicity, or even 
neuroprotective effects of S129-phosphorylation exist [10, 159, 193, 216]. 
The cell possesses several kinases to phosphorylate aSYN at S129 including but not limited 
to polo-like kinases 1-3 (PLK), G protein-coupled receptor kinases (GRK), or leucine-rich 
repeat kinase 2 (LRRK2) [230]. Differential expression of these kinases between neuronal 
subtypes could influence their general vulnerability to PFF induced pathology. The 
significance of aSYN phosphorylation in the pathogenesis of PD needs further clarification. 
4. Extensive axonal arborization and rate of oxidative phosphorylation 
Neurons which are predominantly affected by LB formation in PD such as the dopaminergic 
SNc or the noradrenergic LC possess long, thinly or unmyelinated axons which show 
extensive arborization in their target regions [31, 191, 297]. Thus, axonal hyperbranching has 
been proposed as a key vulnerability factor in PD. 
A recent study by Pacelli and colleagues compared the axonal arborization and oxidative 
phosphorylation capacity of SNc, ventral tegmental, and OB dopaminergic neurons [217]. 
They showed that the most vulnerable SNc neurons have the most extensively arborizing 
axonal tree, whereas the least vulnerable OB neurons have the smallest axonal arbor size 
[217]. They also observed a considerably higher basal oxidative phosphorylation rate of SNc 
neurons compared to OB and ventral tegmental neurons. Remarkably, a reduction of axonal 
arborization of SNc neurons significantly decreased their basal oxidative phosphorylation 
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rate and their vulnerability to the neurotoxin MPP+ indicating that the degree of axonal 
arborization is a key contributor to the vulnerability of neurons [217]. 
Mena-Segovia and colleagues have demonstrated in single-cell tracing studies that cholinergic 
PPN neurons have a highly collaterizing axonal arborization which might contribute to their 
selective vulnerability observed in our PFF model [195]. Studies on GABAergic and 
glutamatergic neurons are to our knowledge not available. However, as GABAergic cells 
seem to function as local interneurons and their axonal projections do not leave the PPN 
region [154], their axonal collateralization is assumably lower. 
5.1.3 Aggregate formation per se does not induce reactive microgliosis 
Since the first description of apparent microgliosis in the SNc of PD patients in 1988 [194], 
the number of studies addressing the role of neuroinflammatory processes in disease 
initiation and progression is ever growing. 
Microglia are the resident immune cells of the CNS making up around 10-20% of adult glial 
cells [168, 289, 293]. Postmortem studies of PD brains have observed the presence of 
activated microglia in various brain regions including but not limited to the SNc, putamen, 
LC, and hippocampus [55, 84, 129, 144, 194]. Additionally, positron emission tomography 
(PET) studies of microglia activation using the translocator protein (TSPO) radioligand 11C-
PK11195 demonstrated early and long-lasting microglial activation in the pons, basal ganglia, 
putamen, and midbrain of PD patients [14, 93, 215]. Remarkably, activation of microglia 
seemed to better correlate with the presence of α-synucleinopathy than neuronal cell loss [78, 
264], which was also confirmed by neuropathological studies [55].  
In our model, injection of PFF’s was accompanied by significant microgliosis at the injection 
site as evidenced by an increase of IbA1-positive pixel count. Microgliosis was already 
evident at the earliest 6-week time-point (Fig. 4.5A), even before significant cholinergic cell 
loss was present (Fig. 4.6A), and persisted without further progression until 12 wpi. 
Remarkably, injection of monomeric aSYN (control) induced a comparable degree of 
microgliosis at the injection site, despite the absence of aggregate formation, and 
neurodegeneration. In contrast to human studies implicating a correlation of the presence of 
intraneuronal aSYN aggregates (LBs) and activated microglia [55], we did not detect 
microgliosis in the contralateral PPN region of PFF injected mice, in spite of p-aSYN 
aggregate formation in cholinergic neurons (Fig. 4.5B). This implicates that in our model, 
intraneuronal aggregate formation per se does not induce activation of microglial cells. 
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In vitro studies showed that extracellular aSYN can act as chemoattractant and damage-
associated molecular pattern (DAMP) inducing activation and recruitment of microglia 
resulting in pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α), elevated expression 
of COX-2 and inducible nitric oxide synthase (iNOS), and elevated free radical production 
[ROS, reactive nitrogen species (RNS)] [170, 253, 295, 328]. The rate of microglial activation 
strongly depended on the structure of aSYN: fibrillar forms of aSYN induced the highest 
level of pro-inflammatory cytokine production and secretion compared to monomeric or 
oligomeric aSYN [123].  
In our model, inoculation of monomeric aSYN or PFF’s into brain parenchyma primarily 
results in high levels of extracellular monomeric aSYN or PFF’s, which, based on the above 
mentioned in vitro studies, likely act as chemoattractants and activators of microglial cells in 
vivo resulting in reactive microgliosis at the injection site. However, in contrast to the in vitro 
studies describing a structure-dependent activity level of microglial cells, we did not detect 
any differences between monomeric aSYN and PFF injected animals in the level of microglia 
activation. Importantly, as the method utilized in this study to investigate microglial 
activation solely measured IbA1-positive pixel count reflecting microglial morphological 
changes (ramified → amoeboid) and microglial proliferation, we might have missed different 
levels of cytokine production in PFF injected animals compared to controls. 
In vivo studies of aSYN overexpression in predetermined neuronal populations either in 
transgenic mouse lines or via rAAV-mediated approaches showed that aSYN overexpression 
alone, even in the absence of overt neurodegeneration, was enough to elicit reactive 
microgliosis [295, 305, 330]. The proposed mechanism of microglial activation in these 
models is neuronal secretion of different forms of aSYN, which then leads to microglial 
recruitment and activation. Neuronal secretion of aSYN is supported by in vitro as well as in 
vivo studies demonstrating that aSYN can be secreted by neurons in an activity-dependent 
manner [4, 69, 70, 345]. 
Remarkably, despite the suggested correlation of α-synucleinopathy and regional activation 
of microglia in human PD brains and aSYN overexpression-based animal models of PD [55, 
100, 263, 295, 305, 330], we did not detect any activation of microglia cells in the 
contralateral, aggregate-containing PPN region of PFF injected mice. Currently, we can only 
speculate about the underlying cause of this discrepancy. The induction of α-synucleinopathy 
in aSYN overexpression and PFF models is substantially different. Whereas overexpression-
based animal models induce supraphysiological aSYN levels, PFF’s trigger the misfolding of 
physiological levels of endogenous aSYN and result in a rather decreased cytoplasmic aSYN 
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level due to the relocalization of the protein to intraneuronal aggregates [213, 322]. Thus, 
neurons overexpressing high amounts of aSYN most likely secrete considerably higher 
amounts of the protein compared to neurons with physiological levels of aSYN. As the 
activation level of microglia correlates with extracellular aSYN concentrations [295], this 
might lead to a differential activity level of microglia in overexpression- and PFF-based 
animal models.  
5.1.4 PFF induced pathology spreads over considerable distances 
A better understanding of the mechanisms and routes of disease progression would provide 
key opportunities to develop disease-modifying (neuroprotective) strategies. Several lines of 
evidence, including the Braak staging scheme and studies of PFF animal models indicate that 
PD pathology spreads in a predictable manner between brain regions sharing considerable 
interconnections [30, 31, 188, 190, 205, 242]. 
Our whole-brain analysis of the propagation pattern of p-aSYN pathology revealed that PFF 
induced pathology was not restricted to the close vicinity of the inoculation site but was 
observed in brain regions far beyond the left PPN region. First p-aSYN aggregates in distant 
brain regions were observable as soon as 1 wpi. At this early time-point, aggregates were 
confined to the ipsilateral (left) hemisphere with only one region being affected bilaterally. 
Thereafter, pathology progressed both in severity and distribution affecting up to 286 brain 
regions at the 6-week time-point. Despite the unilateral injection, aggregates were found 
bilaterally, although the ipsilateral (left) hemisphere was affected more severely. Aggregates 
were distributed throughout the whole brain spanning from the olfactory bulb to the spinal 
cord with the farthest positive region being as far as 7.19 mm away from the injection site. 
We found a strong correlation between the degree of somal and neuritic pathology at 1 as 
well as 6 wpi, indicating that the neuritic Lewy-like pathology most likely represents axonal 
p-aSYN pathology of those neurons who exhibit somatic inclusions. Monomeric aSYN 
injected animals were devoid of p-aSYN aggregates indicating that the conformational 
difference of monomeric (soluble) aSYN and PFF is crucial in the induction of pathology. 
Simple diffusion of the injected PFF’s in the brain parenchyma and cerebrospinal fluid is an 
unlike explanation of the seeding effect in distant brain regions. Upon simple diffusion, due 
to the dose-dependency of the aggregative potential of PFF’s [102], one would expect severe 
pathology in close proximity to the injection site, which would gradually decrease with longer 
distances from the primary inoculation. This expected gradient of pathology was not evident 
in our analysis as we did not observe any regularity in the severity of p-aSYN pathology and 
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the distance from the injection site (Fig. 4.7B,C). A confounding factor is certainly the 
selective vulnerability pattern of different neuronal populations which would likely influence 
this expected gradient of pathology (see chapter 5.1.2). However, the dopaminergic SNc, 
which lays in close proximity to the injection site (0.56 mm rostral from the PPN), and shows 
considerable vulnerability to PFF induced pathology in animal models [179, 189, 223], did 
not display any pathology 1 wpi and only moderate pathology 6 wpi. Additionally, affection 
of the contralateral hemisphere cannot be explained by simple diffusion of PFF’s. 
A more likely explanation of the observed brain-wide pathology is axonal transport and cell-
to-cell transmission of PFF’s within interconnected neuronal circuits. In vitro, microfluidic 
chambers can be used to separate axonal projections from perikarya of cultured neurons and 
additionally prevent diffusion of PFF’s between chambers. Studies utilizing this system 
showed that PFF’s can be transported in the anterograde and retrograde direction and 
second-order neurons primarily not exposed to exogenous PFF’s can readily acquire 
aggregates indicative of cell-to-cell transmission of pathological aSYN species within 
neuronal interconnections [83, 102, 320]. Under in vivo conditions, injection of human 
monomeric aSYN into the OB of mice resulted in fast transport of the protein to brain 
regions sharing strong interconnections with the primary inoculation site in less than one 
hour [241]. Additionally, further in vivo studies evidenced interneuronal transmission of 
pathogenic aSYN species as a likely event in disease progression. Animal studies modeling 
intrastriatal dopaminergic cell transplantation observed the transfer of host-derived aSYN to 
engrafted neurons which can only be explained by cell-to-cell transmission of the protein [6, 
62, 111, 150].  
In an elegant set of experiments, Okuzumi and colleagues demonstrated that propagation of 
PFF’s in the murine brain strongly depends on the integrity of axonal interconnections [210]. 
They performed corpus callosotomy6 prior to unilateral PFF injection into the dorsal 
striatum and compared the brain-wide propagation pattern of p-aSYN pathology in mice 
with and without callosotomy [210]. They observed significant reduction of p-aSYN 
aggregates in the contralateral hemisphere in animals that underwent callosotomy prior to 
PFF inoculation compared to animals without callosotomy [210]. As the corpus callosum 
comprises the major commissural fiber tract connecting the two hemispheres, this highly 
indicates that propagation of PFF pathology depends on intact neuronal interconnections.  
                                                 
6 Corpus callosotomy: surgical intervention in which the corpus callosum is cut through. 
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Our results of the brain-wide propagation pattern of PFF induced pathology is consistent 
with the proposed progression of pathology within given neuronal circuits as regions 
developing p-aSYN aggregate pathology lay all within the known anterograde- or retrograde 
connectomes of the PPN. However, it must be noted that not all interconnected regions 
developed pathology indicating that factors other than synaptic interconnectivity may also 
play a crucial role in determining the route of pathological aSYN progression. For example, 
the thalamus is a major output structure of both the cholinergic and glutamatergic PPN [59, 
154, 196], nevertheless, no or only sparse pathology was observed 1 and 6 wpi. Similarly, 
although the SNr strongly innervates glutamatergic PPN neurons [254], it was almost devoid 
of pathology at all examined time-points.  
Currently, we can only speculate about the additional factors determining pathology spread 
in our model. These certainly include the selective vulnerability factors mentioned in chapter 
5.1.2, which might influence the degree of evolving pathology due to extracellular and 
intracellular PFF exposure. Additionally, further factors might impact the acquisition and 
degree of pathology in interconnected brain regions. These include: (1) strength of synaptic 
interconnectivity; (2) the firing frequency of the interconnected neuron, as higher firing 
frequencies might lead to increased PFF endocytosis due to increased rate of vesicle 
membrane recycling [29]; (3) the degree of myelination of PFF exposed axons, as the myelin 
sheath might act as a physical barrier against PFF’s [205]. 
5.2 The rAAV-model of Parkinson’s disease 
In this part of the study we showed that targeted, viral vector mediated overexpression of 
human mutated A53T-aSYN in the noradrenergic LC led to widespread axonal transport of 
human aSYN to distant brain regions. 
5.2.1 Human aSYN progression is consistent with axonal transport 
Our whole-brain analysis of human aSYN progression following successful viral vector 
mediated protein expression in the LC region revealed widespread axonal human aSYN 
signal in A53T-aSYN overexpressing animals as soon as 1 wpi, which progressed significantly 
to later time-points. Despite the unilateral vector injection, signal was also abundantly found 
in the contralateral hemisphere. However, aSYN-positive axons were more abundantly 
found ipsilaterally. Human aSYN was solely found in axons and synaptic boutons, no cells 
(neurons or glia) showed somatic human aSYN immunoreactivity distant from the injection 
Discussion 
78 
site. Remarkably, no p-aSYN, p62, or Ubi-1-positive pathological forms of aSYN were 
detectable at any examined time-point. Additionally, no axonal labeling of the control protein 
Luciferase was found at any time-point distant from the injection site, which might be due 
to its significantly higher molecular weight (Luciferase 62 kDa vs. aSYN 15 kDa), or due to 
the physiological presynaptic localization of aSYN. 
The distribution of axonal signal in our model is consistent with intra-axonal, anterograde 
transport of human aSYN to the respective output regions of the primarily transduced LC, 
and partly parabrachial and vestibular nuclei. This finding is consistent with previous studies 
reporting human aSYN transport within the axonal fields of the mesencephalic dopaminergic 
system following successful transduction of SNc and ventral tegmental neurons [60, 131, 
142, 147]. 
Previous studies report a cell-to-cell transmission of overexpressed aSYN in the murine 
brain. One study showed that striatal engrafted fetal rat ventral mesencephalic neurons 
acquired human aSYN following viral vector mediated overexpression of the protein in 
adjacent brain regions [150]. Additionally, Ulusoy and colleagues reported neuron-to-neuron 
transmission of human aSYN following targeted overexpression of human aSYN in the 
cholinergic vagal nerve and its neuronal cell bodies (dorsal motor nucleus of the vagal nerve, 
and nucleus ambiguus) [255, 311]. We did not detect any human aSYN-immunoreactivity in 
cell bodies outside the primarily transduced LC region at any investigated time-point, which 
argues against interneuronal transport of aSYN in our overexpression-based animal model. 
This is in line with the finding that despite abundant axonal human aSYN-pathology in the 
SNc region of A53T-aSYN overexpressing mice, we did not detect any alterations of 
dopaminergic neuronal cell counts between aSYN and Luciferase injected animals. To detect 
spread of human aSYN and consequent cellular loss in target regions in the model, longer 
observational periods might be needed. 
Interestingly, no p-aSYN signal was found in distant brain regions, neither axonally nor in 
cell bodies. This is especially intriguing as the LC region showed abundant and progressive 
intraneuronal accumulation of p-aSYN in primarily transduced neurons [116]. The 
underlying cause of this discrepancy is not known. However, as phosphorylation at specific 
residues of proteins might change their axonal transport rates [57, 250], the disparity between 
the p-aSYN labeling of the cell body and the axons might therefore stem from different 
efficacy in axonal transport of non-phosphorylated and phosphorylated aSYN, which was 
already reported in cell culture systems [258]. Therefore, axonal p-aSYN might be apparent 
at later observational time-point, which is in line with a previous study of a nigral 
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overexpression model showing p-aSYN immunoreactivity in a subset of human aSYN-
positive axons 13 wpi [344]. 
5.3 Comparison of the spreading pattern of two PD models 
In this study, the propagation pattern of induced pathology was investigated in two different 
types of PD animal models.  
In the PFF model of PD, PFF’s were injected unilaterally into the left PPN region of mice 
inducing progressive recruitment of endogenous, primarily soluble aSYN into p-aSYN- and 
p62-positive, PK resistant aggregates. PFF-induced pathology was not confined to the 
injection site but also spread over considerable distances to brain regions far beyond the left 
PPN region. P-aSYN-positive inclusions were found bilaterally, both in perikarya of neurons 
reminiscent of human LBs (somal pathology), and in axons reminiscent of human LNs 
(neuritic pathology). The propagation pattern of pathology was consistent with trans-
neuronal transport of pathological aSYN species within interconnected neuronal circuits.  
In the rAAV mediated overexpression based animal model of PD, human A53T-aSYN 
expressing rAAV vectors were injected into the right LC region of mice inducing robust 
human aSYN overexpression at the injection site. The supraphysiological levels of aSYN 
resulted in severe aSYN pathology at the injection site in form of progressive accumulation 
of p-aSYN, and p62- and Ubi-1-positive aggregates [116]. However, in stark contrast to the 
PFF model of PD, distant brain regions were devoid of p-aSYN immunoreactivity. 
Moreover, although robust human aSYN signal was found in brain regions distant from the 
injection site, immunoreactivity was confined to axons most likely of the primarily 
transduced pontine tegmental neurons, and was not found in cell bodies apart from the 
inoculation site. This finding implicates that in the human aSYN overexpression based 
model, trans-neuronal transport of human aSYN did not take place or remained under the 
detection threshold in the time-frame of 9 weeks. 
The reason for this difference in the two models most likely lies within the high dissimilarity 
of the approaches by which α-synucleinopathy was induced in vivo. In the PFF model, 
nucleation-dependent aggregation of endogenous aSYN is triggered by addition of 
exogenous protein seeds (PFF’s). In this scenario, the templated misfolding of physiological 
levels of intracellular aSYN takes place most likely resulting in lower aSYN concentration 
due to its relocalization to aggregates [213]. In vitro experiments with microfluidic neuronal 
cultures reported efficient anterograde and retrograde transport of both oligomeric aSYN 
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and aSYN fibrils [32, 83]. Moreover, second order neurons in the axonal chamber acquired 
exogenously added PFF’s which seeded the recruitment of endogenous aSYN [83, 183]. This 
highly implicates that the seeding potential of PFF’s is maintained even after axonal- and 
interneuronal transport. 
In the viral vector mediated model, loco-regionally injected rAAV vectors induce the 
overexpression of human aSYN resulting in supraphysiological levels of intracellular aSYN. 
The exact mechanisms of aSYN aggregate formation in these models are unknown, but 
might include concentration-dependent aggregation of aSYN, and overburden and 
disruption of the protein degradation systems, i.e. the proteasomal and autophagy-lysosomal 
systems. Cell culture models of inducible overexpression of aSYN showed that soluble 
monomeric and oligomeric aSYN are readily detectable in the supernatant indicating 
secretion of cell-produced aSYN [69]. Interestingly, purified fractions of the secreted aSYN 
could only be internalized by proliferating, but not by differentiated SH-SY5Y cells or 
primary cortical neurons [69]. Additionally, even after cellular uptake of extracellular aSYN 
species, no aggregate formation was detected in these cells [69]. These results translate well 
into our in vivo model of aSYN overexpression, where no pathological aggregates were found 
distant from the injection site. Although highly speculative, but the results might indicate 
that the aSYN species formed within overexpressing neurons are not readily transmissible 
between neuronal populations and that they do not possess prion-like properties and 
therefore cannot induce the templated misfolding of endogenous aSYN [309]. 
5.4 Limitations of the study 
A number of limitations of this study have to be considered. First, the primary induction site 
of the focal α-synucleinopathy was different in the two investigated animal models of PD. 
Whereas PFF’s were injected into the neurochemically heterogeneous ponto-mesencephalic 
PPN, viral vector mediated overexpression of A53T-aSYN was induced in the mainly 
noradrenergic LC. These two brain nuclei, although sharing some common features, exhibit 
significant differences including neurochemical properties, wiring architecture, and 
electrophysiological properties. One might hypothesize that the essentially different 
propagation pattern of α-synucleinopathy in the two PD models might be partly or even 
entirely attributable to the inherent differences of PPN and LC neurons. This limits the 
generalizability of the results, and therefore, the results should be interpreted as preliminary. 
Further investigations are needed to confirm the significantly different propagation pattern 
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of PFF and rAAV induced focal α-synucleinopathy. Accordingly, we plan to inject PFF’s 
into the noradrenergic LC region, and rAAV-A53T-aSYN into the PPN region of mice in a 
follow-up study to confirm our preliminary results.  
Second, we used different aSYN species in the two parts of the study. In the LC, 
overexpression of human mutant A53T-aSYN was induced via viral vector mediated 
overexpression, whereas PFF’s were generated from mouse aSYN. Human wild-type and 
mouse aSYN differ in only six out of 140 amino acid residues and are therefore 95.7% 
homologous [167]. The amino acid alanine is found at position 53 in wild-type human aSYN, 
and a subtitution of alanine to threonine causes autosomal dominantly inherited PD (A53T-
aSYN) [229]. Remarkably, threonine is the naturally occurring amino acid at position 53 in 
rodents, hence, A53T-aSYN and mouse aSYN differ in only five amino acids and therefore 
share a 96.4% homology [167]. Despite this high homology, partial species barrier was 
evidenced by several studies which showed that injection of PFF’s generated from human 
aSYN showed less efficiency in inducing local and brain-wide pathology in wild-type mice 
compared to PFF’s generated from mouse aSYN [180, 189, 242]. The lack of intercellularly 
transmitted pathological aSYN species in the rAAV model of PD might therefore stem from 
the partial species barrier between mice and humans. Hence, further studies are required in 
which endogenous mouse aSYN is overexpressed in the LC and/or the PPN to confirm our 
preliminary results. 
5.5 Conclusions and outlook 
PD is a highly debilitating disorder significantly decreasing the quality of life of patients and 
their caregivers.  The ultimate goal of both preclinical and clinical research is to finally be 
able to prevent disease initiation, or, if the disease has been already initiated, to slow down 
or even halt the disease progression.  
The long-term objectives of the establishment of new disease models are multiple: (1) 
studying mechanisms underlying disease initiation, or disease progression to provide new 
targets for the development of disease-modifying therapy; (2) testing of newly developed 
compounds concerning efficacy and toxicity. 
The most intriguing finding of the herein presented study is the selective vulnerability pattern 
of distinct PPN neuronal subpopulations. We showed that cholinergic PPN neurons were 
significantly more vulnerable to extracellular PFF’s compared to GABAergic or 
glutamatergic PPN neurons, as most of the intracellular p-aSYN inclusion bodies were 
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located in cholinergics leading to their selective degeneration. Further research is needed to 
determine the factors which render cholinergic neurons particularly susceptible to the disease 
process, or, on the contrary, render GABAergic and glutamatergic neurons partially resilient 
to extracellular PFF’s. The mechanisms underlying differential vulnerability might include: 
‒ heterogeneity at the molecular level, which could be elucidated via comparative 
expression profiling at the single-cell level; 
‒ differential electrophysiological properties, which could be investigated with single-cell 
patch clamp recordings; 
‒ distinct bioenergetic requirements, which could be elucidated via measurements of 
basal oxidative phosphorylation, reserve capacity, and mitochondrial density; 
‒ morphological features, e.g. the degree of axonal arborization. 
Elucidation of the exact mechanisms underlying the differential vulnerability pattern of 
neuronal subpopulations holds great potential for the identification of novel drug targets for 
the development of disease-modifying therapy. 
Analysis of the brain-wide spreading pattern of PFF induced pathology implicated that 
pathological aSYN species do not propagate indiscriminately. One of the major determinants 
of the propagation pattern is the wiring architecture, i.e. the connectome of the primarily 
targeted brain region, since all the structures developing p-aSYN inclusions lay within the 
known synaptic connections of the PPN. However, connectivity per se cannot explain the full 
extent of pathology as brain regions sharing strong synaptic interconnectivity, such as the 
SNr or the thalamus showed only sparse pathology, whereas brain regions loosely connected 
to the PPN, such as the bed nuclei of the stria terminalis or the central amygdala showed 
severe pathology. Further research is needed to resolve additional determinants of pathology 
progression as understanding the mechanisms underlying pathology propagation would 
provide valuable knowledge for the development of neuroprotective therapies aimed at 
decelerating disease progression. 
The comparison of the PFF-induced and rAAV-mediated overexpression based PD animal 
models revealed fundamental differences in the brain-wide propagation patterns in the two 
models. Whereas in the PFF model, trans-synaptic, cell-to-cell transmission of aggregation-
prone aSYN species could be undoubtedly observed, in the targeted overexpression-based 
model, no pathological aSYN could be observed apart from the injection site. Although 
trans-synaptic transport of human, non-aggregated aSYN has been reported in previous 
studies [311], this could not be definitely proven (or disproven) in our model. 
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Both models recapitulate several features of human PD, however, based on the differences 
of available outcome measures in the two models, their eligibility for preclinical testing of 
potentially disease-modifying compounds is different. For example, as in the PFF model 
aggregation-prone aSYN species are transported trans-synaptically, the model is appropriate 
to test antibody therapies targeting extracellular aSYN, as opposed to the rAAV-based 
model, which, due to the lack of pathological aSYN propagation, is not suited in its present 
form. 
Taken together, this study provides a valuable starting point for further research on cellular 
vulnerability factors and mechanisms of disease progression, which hold great potential for 
the identification of novel drug targets aimed at disease-modification rather than symptom 
alleviation. Additionally, both animal models provide valuable tools for testing of newly 








Parkinson's disease is a highly debilitating disorder classically characterized by the 
degeneration of dopaminergic midbrain neurons of the substantia nigra. The resulting 
nigrostriatal dopamine deficiency is thought to be responsible for the onset of the cardinal 
Parkinson's motor symptomtomatology; bradykinesia, rigidity, and resting tremor. However, 
recent studies show that Parkinson's disease is a multisystem disorder. Thus, it comes not 
only to degeneration in the nigrostriatal system, but also to pronounced cell loss in many 
other brain regions. Histopathologically, Parkinson's disease is characterized by the presence 
of so-called Lewy bodies or neurites. These are intracytoplasmic proteinaceous inclusions 
consisting mainly of aggregated α-synuclein. Two neuronal structures that both have 
pronounced Lewy pathology in Parkinson's disease and prominent neurodegeneration are 
the noradrenergic locus coeruleus and the neurochemically heterogeneous pedunculopontine 
nucleus. Remarkably, in the pedunculopontine nucleus Lewy pathology and 
neurodegeneration are predominantly restricted to the cholinergic cell population, while the 
GABAergic and glutamatergic cell groups exhibit only minor Lewy pathology and are largely 
spared of neurodegeneration. 
The present dissertation pursued two main goals. On the one hand, we investigated whether 
the selective vulnerability pattern of the cholinergic subpopulation of the pedunculopontine 
nucleus could be reproduced in a mouse model based on the intracerebral injection of 
preformed α-synuclein fibrils. Second, the brain-spreading pattern of two focal-induced α-
synucleinopathy mouse models were compared with respect to the methodology used to 
initiate the aggregation process (vector-mediated overexpression vs. α-synuclein fibril 
model). 
In the first part of the study, we used a targeted intracerebral injection of preformed α-
synuclein fibrils to induce a focal α-synucleinopathy in the pedunculopontine nucleus. Our 
data show that the injection of α-synuclein fibrils resulted in the recruitment and misfolding 
of endogenous α-synuclein leading to formation of Lewy body-like aggregates in neuronal 
perikarya and axons. Interestingly, the observed inclusion bodies were immunoreactive for 
S129-phosphorylated α-synuclein, p62 positive and resistant to proteinase K digestion. We 
thereby showed that the experimentally induced α-synuclein pathology possessed several key 
features of human Lewy pathology. Remarkably, the major burden of Lewy-like pathology 
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and quantified cell loss was limited to the cholinergic subpopulation of the pedunculopontine 
nucleus, while the non-cholinergic neurons were largely spared of Lewy pathology and 
degeneration at any investigated time-point. Interestingly, in both fibril and monomer-α-
synuclein (control) injected animals, induction of reactive microgliosis occurred, although no 
α-synuclein pathology was observed in the control group. Our analysis also showed that the 
formation of α-synuclein pathology was not limited to the immediate vicinity of the site of 
injection, but propageted over considerable distances to other interconnected brain regions. 
Since α-synuclein positive aggregates were found in neuronal cell bodies of distant brain 
regions, which lay all within the neuronal network of the pedunculopontine nucleus, it can 
be concluded that the α-synucleinopathy spread only within the neural network of the 
pedunculopontine nucleus. 
In the second part of the thesis, focal α-synucleinopathy was induced in the locus coeruleus 
by intracerebral injection of adeno-associated viral vectors containing the gene for human 
mutant A53T-α-synuclein or luciferase (control protein). The obtained data showed that local 
overexpression of human α-synuclein led to widespread propagation of the protein 
consistent with anterograde axonal transport. Analysis of the α-synuclein propagation pattern 
demonstrated that the brain-wide α-synucleinopathy was confined to the output regions of 
the noradrenergic locus coeruleus. Furthermore, there was no evidence of cell-to-cell 
transmission of human α-synuclein. Based on these findings we concluded that the induced 
Lewy-like pathology did not leave the noradrenergic locus coeruleus system in the studied 
time frame of 9 weeks. In addition, unbiased stereological quantification of the dopaminergic 
substantia nigra revealed no significant cell loss at the relatively short time-frame of 9 weeks. 
In conclusion, the studies presented in this dissertation show that cholinergic 
pedunculopontine neurons are significantly more vulnerable to α-synuclein fibril-induced α-
synucleinopathy than non-cholinergic neurons. In addition, we were able to show that the 
brain-wide progression pattern of Lewy-like pathology is significantly different between the 
two studied α-synucleinopathy models. While in the fibril model the α-synucleinopathy 
pattern was consistent with cell-to-cell transmission of pathological α-synuclein species, we 
only observed axonal transport of α-synuclein but not cell-to-cell transmission in the 
overexpression-based model. The studies carried out within this dissertation therefore 
provide a valuable starting point for the further investigation of cellular vulnerability factors 






Die Parkinson-Krankheit ist eine hochgradig einschränkende Erkrankung, die 
klassischerweise durch die Degeneration dopaminerger Mittelhirnneurone der Substantia 
nigra gekennzeichnet wird. Der daraus resultierende Mangel an striatonigralem Dopamin 
wird als ursächlich für das Entstehen der kardinalen Parkinson-Symptomatik – Bradykinesie, 
Rigidität und Ruhezittern – aufgefasst. Neuere Untersuchungen belegen jedoch, dass es sich 
bei der Parkinson-Krankheit um eine Multisystemerkrankung handelt. So kommt es nicht 
nur zur Degeneration im striatonigralen System, sondern auch zu ausgeprägten 
Zellverlussten in vielen weiteren Hirnregionen. Histopathologisch ist die Parkinson-
Krankheit durch das Vorhandensein sogenannter Lewy-Körperchen oder –Neurite 
gekennzeichnet. Es handelt sich hierbei um intrazytoplasmatische proteinhaltige 
Einschlüsse, die hauptsächlich aus aggregiertem α-Synuclein bestehen. Zwei neuronale 
Strukturen, die im Rahmen der Parkinson-Krankheit sowohl eine ausgeprägte Lewy-
Pathologie besitzen, wie auch eine prominente Neurodegeneration aufweisen, sind der 
noradrenerge locus coeruleus und der neurochemisch heterogene pedunculopontine Kern. 
Bemerkenswerterweise beschränken sich im pedunculopontinen Kern Lewy-Pathologie und 
Neurodegeneration jedoch überwiegend auf die cholinerge Zellpopulation, so weisen die 
GABAergen und glutamatergen Zellgruppen kaum Lewy-Pathologie auf und bleiben auch 
von der neurodegeneration weitestgehend verschont. 
Die hier vorliegende Dissertation verfolgte zwei Hauptziele. Zum einen sollte untersucht 
werden, ob das selektive Vulnerabilitätsmuster der cholinergen Subpopulation des 
pedunculopontinen Kerns in einem Mausmodell, welches auf der intrazerebralen Injektion 
von präformierten α-Synuclein-Fibrillen basiert, reproduziert werden kann. Zweitens sollte 
das hirnweite Ausbreitungsmuster von zwei fokal induzierten α-Synucleinopathie-
Mausmodellen im Hinblick auf die verwendete Methodik zur Initiierung des 
Aggregationsprozesses (vektor-vermittelte Überexpression vs. α-Synuclein-Fibrillenmodell) 
verglichen werden.  
Im ersten Teil der Studie wurde durch gezielte intrazerebrale Injektion von präformierten α-
Synuclein-Fibrillen eine fokale α-Synucleinopathie im pedunculopontinen Kern induziert. 
Die gewonnenen Daten zeigen, dass es durch die Injektion der α-Synuclein-Fibrillen zu einer 
Rekrutierung und Fehlfaltung von endogenem α-Synuclein kam, was zu Lewy-Körperchen 
artigen Aggregaten in neuronalen Perikarya und Axonen führte. Interessanterweise waren die 
beobachteten Einschlusskörperchen immunreaktiv gegen S129-phosphoryliertes α-
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Synuclein, p62 positiv und resistent gegen Proteinase K Verdauung. Es konnte hierdurch 
gezeigt werden, dass die experimentell induzierte α-Synuclein-Pathologie mehrere 
Schlüsselmerkmale der humanen Lewy-Pathologie besaß. Bemerkenswerterweise war die 
Hauptlast der Lewy-ähnlichen Pathologie und der quantifizierte Zellverlust auf die 
cholinerge Subpopulation des pedunculopontinen Kerns beschränkt. Die nicht-cholinergen 
Neurone blieben größtenteils von der Aggregatbildung verschont und wiesen zu keinem 
untersuchten Zeitpunkt einen Zellverlust auf. Interessanterweise kam es sowohl bei Fibrillen 
injezierten als auch bei monomer α-Synuclein (Kontrolle) injizierten Tieren zur Induktion 
einer reaktiven Mikrogliose, obwohl in der Kontrollgruppe keine α-Synuclein-Pathologie 
beobachtet wurde. Unsere Analysen zeigten weiterhin, dass die Bildung der α-Synuclein-
Pathologie nicht nur auf die unmittelbare Nähe der Injektionsstelle beschränkt war, sondern 
sich sich über beträchtliche Entfernungen in andere Hirnregionen ausbreitete. Da die 
Aggregate nur in neuronalen Zellkörpern entfernter Gehirnregionen gefunden wurden, die 
alle innerhalb des neuronalen Netzwerkes des Pedunculopontinen Kerns lagen, kann aus den 
Daten geschlossen werden, dass sich die α-Synucleinopathie innerhalb des Konnektoms des 
Pedunculopontinen Kerns ausbreitet.  
Im zweiten Teil der Dissertation wurde erstmals eine fokale α-Synucleinopathie im Locus 
coeruleus durch intrazerebrale Injektion von Adeno-assoziierten viralen Vektoren induziert, 
die das Gen für humanes mutiertes A53T-α-Synuclein oder Luciferase (Kontrollprotein) 
enthielten. Die hierdurch gewonnenen Daten zeigten, dass es im Rahmen einer lokalen 
Überexpression von humanem α-Synuclein zu einer raschen axonalen Ausbreitung des 
Proteins kommt. Die Analyse des Ausbreitungsmusters konnte aufzeigen, dass die 
gehirnweite α-Synucleinopathie auf die Outputregionen des noradrenergen locus coeruleus 
beschränkt war und gleichzeitig keine Hinweise auf eine Zell-zu-Zell-Übertragung von 
menschlichem α-Synuclein vorlagen. Hieraus schlussfolgerten wir, dass die induzierte 
Pathologie das noradrenerge locus coeruleus System im untersuchten Zeitrahmen von 9 
Wochen nicht verließ. Desweiteren zeigte sich im Rahmen der stereologischen 
Quantifizierung der dopaminergen Substantia nigra Neurone, in dem relativ kurzen Zeitraum 
von 9 Wochen, kein signifikanter Zellverlust. 
Zusammengefasst belegen die hier vorgestellten Studien, dass cholinerge pedunculopontine 
Neurone signifikant vulnerabler gegenüber einer mittels α-Synuclein-Fibrillen induzierten α-
Synucleinopathie sind als nicht-cholinerge Neurone. Zusätzlich konnten wir zeigen, dass das 
hirnweite Progressionsmuster der Pathologie in den zwei untersuchten α-Synucleinopathie-
Modellen signifikant unterschiedlich ist. Während im Fibrillenmodell das α-
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Synucleinopathiemuster mit einer Zell-zu-Zell-Übertragung von pathologischen α-
Synuclein-Spezies vereinbar war, konnte im überexpressionsbasierten Modell lediglich ein 
axonaler Transport von α-Synuclein, aber nicht eine Zell-zu-Zell-Übertragung nachgewiesen 
werden. Die innerhalb dieser Dissertation durchgeführten Studien stellen daher einen 
wertvollen Ausgangspunkt für die weitere Erforschung von zellulären 
Vulnerabilitätsfaktoren und Mechanismen des Krankheitsverlaufs dar. 
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7 List of abbreviations 
7.1 Abbreviations in the main text
6-OHDA 6-hydroxydopamine 
AON anterior olfactory nucleus 
ARAS ascending reticular arousal system 
aSYN α-synuclein 
ATP adenosine triphosphate 
CBA chicken β-actin 
ChAT choline acetyltransferase 
CMV cytomegalovirus 




DAT dopamine transporter 
DBS deep brain stimulation 
dsDNA double-stranded DNA 
GABA γ-aminobutyric acid 
GI gastrointestinal 
GPi globus pallidus internus 
GRK G protein-coupled receptor kinase 
GRN gigantocellular nucleus 
LAG3 lymphocyte-activation gene 3 
LB Lewy-body 
LC locus coeruleus 
LN Lewy-neurite 
LRRK2 leucine-rich repeat kinase 2 
LV lentivirus 
MAO monoamine oxidase 
MDS Movement Disorders Society 










MRI magnetic resonance imaging 
NDS normal donkey serum 
NET noradrenaline transporter 
NeuN neuron N 
NHP non-human primate 
NM neuromelanin 
NMS non-motor symptoms 
OB olfactory bulb 
p-aSYN phosphorylated α-synuclein 
PB phosphate buffer 
PB parabrachial nucleus 
PBS phosphate buffered saline 
PBT phosphate buffered saline with 
Triton X-100 
PD Parkinson’s disease 
PET positron emission tomography 
PFA paraformaldehyde 
PFF preformed fibril 
PK proteinase K 
PLK polo-like kinase 
PPN pedunculopontine nucleus 
PrPC native form of the prion protein 
PrPSc misfolded prion protein 
rAAV recombinant adeno-associated virus 
RBD REM sleep behavior disorder 
RNS reactive nitrogen species 
ROI region of interest 
ROS reactive oxygen species 
SNc substantia nigra pars compacta 
SNr substantia nigra pars reticulata 
ssDNA single-stranded DNA 
STN subthalamic nucleus 
STR striatum 
TH tyrosine hydroxylase 
TU tuberal nucleus 
VTA ventral tegmental area 
wpi weeks post-injection 
WT wild-type 
List of abbreviations 
90 
 
7.2 Abbreviations in the figures 
ACB nucleus accumbens 
aco anterior commissure 
AP area postrema 
APN anterior pretectal nucleus 
BST bed nuclei of the stria terminalis 
BSTov bed nuclei of the stria terminalis, 
anterior division, oval nucleus 
CEA central amygdala 
CEAl central amygdala, lateral part 





CU cuneate nucleus 
DG dentate gyrus 
DMV dorsal motor nucleus of the vagal 
nerve 
ECU external cuneate nucleus 
Epd endopiriform nucleus, dorsal part 
fi fimbria hippocampi 
GP globus pallidus 
HPF hippocampal formation 
HY hypothalamus 
IC inferior colliculus 
icp inferior cerebellar peduncle 
int internal capsule 
IO inferior olivary complex 
ipsi ipsilateral 
IRN intermediate reticular nucleus 
L left 
LHA lateral hypothalamic area 
LRN lateral reticular nucleus 
LS lateral septal nucleus 
MDRNd medullary reticular nucleus, dorsal 
part 
MDRNv medullary reticular nucleus, 
ventral part 
mlf medial longitudinal fascicle 
MOBgr main olfactory bulb, granule layer 
MOBipl main olfactory bulb, inner 
plexiform layer 
MOBopl main olfactory bulb, outer 
plexiform layer 
mono monomeric α-synuclein 
MRN midbrain reticular nucleus 
MRN midbrainr eticular nucleus 
MS medial septal nucleus 
NDB diagonal band nucleus 
NLL nucleus of the lateral lemniscus 
OT olfactory tubercle 
PAG periaqueductal gray 
PB parabrachial nucleus 




RA raphe nuclei 
RR retrorubral field 
sAMY striatumlike amygdalar nuclei 
SC superior colliculus 
SCm superior colliculus, motor related 
SI substantia innominata 
sptV spinal tract of the trigeminal nerve 
SPV spinal nucleus of the trigeminal 
TH thalamus 
TTd taenia tecta, dorsal part 
TU tuberal nucleus 
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